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 Hypertrophic and restrictive cardiomyopathies are congenital cardiac 
diseases that have an incidence of over one in five hundred and may lead to 
sudden cardiac death.  One of the main impediments to directed treatment is an 
incomplete understanding of the transition from mutation to disease morphology 
and hemodynamics, resulting in largely symptomatic treatment.   This project 
sought to understand the molecular mechanisms related to muscle regulation 
that underlie the disease phenotype.  We utilized an in vitro system with 
reconstituted myofilaments to determine the distribution of actomyosin states.  
We examined the effects of protein kinase C phosphorylation of troponin I using 
a glutamate mutation mimicking constitutive phosphorylation.  We showed that 
this modification stabilized the inactive state of actin, without altering the rate of 
  
the active pathway.  Shifting between actin states is a common method of 
altering myocardial regulation among a group of cardiomyopathy causing 
mutations.  These mutations can shift the distribution between states to the 
active, inactive or intermediate state.  We also showed that there is no change in 
the rate of the active pathway.  Thus, the normal equilibrium is essential for 
proper cardiac muscle function, and any disturbance can lead to disease.  We 
determined that there were three functional states of regulated actomyosin.  
Although there has been a widespread consensus that there are three structural 
states, there has been no evidence to show that each of these states has a 
unique function.  Several of the mutations studied in this project provide evidence 
that there is a third functional state, and that stabilization of this state can lead to 
cardiomyopathy.  We narrowed the parameters defining the third state.  This 
state has an ATPase activity between 4-15% of the active state.  Previous 
studies of the underlying molecular mechanism have not been able to explain 
changes in ATPase rates or find a common regulatory change.  By determining 
the individual properties of each state along with their distributions in disease, 
this project advances the search for therapeutic agents that reverse the abnormal 
distributions, possibly reversing the changes seen in patient cardiac muscle by 
targeting the primary pathology. 
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 CHAPTER I:  GENERAL INTRODUCTION 
Congenital cardiomyopathies are among the leading causes of sudden 
cardiac death, and account for a large portion of cardiac fatalities in young 
patients.  Hypertrophic cardiomyopathy (HCM) is the most significant type of 
congenital cardiomyopathy with an incidence of 1 in 500, while restrictive (RCM) 
and dilated cardiomyopathies have lower incidences (Drory et al. 1991; Haber. 
1995; Rose. 2006).  Although there is heterogeneity between patients diagnosed 
with HCM, a majority of them will present with some combination of common 
pathologies (Maron et al. 2003a; Rose. 2006).  Considering that there are several 
hundred disease causing mutations, this overlap indicates a common mechanism 
underlying the disease.  This molecular mechanism underlying the secondary 
changes of cardiomyopathies remains poorly understood (Seidman and 
Seidman. 2001; Ahmad et al. 2005).  A more detailed understanding of this 
alteration in regulation will lead to more effective therapy by targeting the primary 
cause of the disease, instead of the secondary symptoms. 
Hypertrophic Cardiomyopathy 
Genetics 
There are over 200 mutations that cause hypertrophic cardiomyopathy, 
the vast majority of which occur on sarcomeric genes (see 
http://cardiogenomics.med.harvard.edu/project-detail?project_id=230#data for a 
comprehensive list of cardiomyopathy-causing mutations).  These eleven genes 
include β-myosin heavy chain, troponin I, troponin T, and tropomyosin amongst 
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others.  The mutations are generally autosomal dominant, with incomplete 
penetrance (Rose. 2006).  There are correlations among the site of mutation and 
clinical outcome, penetrance, and cardiac morphology.  Several of the troponin 
mutations have a higher mortality rate compared to other cases of 
cardiomyopathy (Watkins et al. 1995; Maron. 2002).   
Genetic analysis has shown that around thirty percent of cases presenting 
as HCM have no apparent mutation on the sarcomeric genes (Arad et al. 2002).  
In some cases the mutation may not yet have been detected, although it is likely 
that other mutations on non-sarcomeric genes may clinically mimic HCM (Ahmad 
et al. 2005).   
Pathology of Hypertrophic Cardiomyopathy 
HCM is characterized by hypertrophy of the ventricular walls, fibrosis, 
myofibrillar disarray, ventricular outflow obstruction, arrhythmias, and heart 
failure (Seidman and Seidman. 2001; Maron. 2002; Maron et al. 2003a; Rose. 
2006).  Many of the presenting clinical and pathological changes are due to the 
release of secondary messengers, as a systemic reaction to the hemodynamic 
instability caused by a hypertrophic, obstructed heart.   
Although a congenital disease, HCM does not manifest in most cases until 
the pubescent growth spurt.  The age of presentation depends to some extent on 
the type of mutation; mutations of myosin binding protein C may remain silent 
until middle or old age, while other mutations present in childhood (Maron et al. 
1986; Niimura et al. 1998).  Patients who present at a young age have a worse 
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prognosis over time versus those presenting as adults.  The majority of cases are 
detected by echocardiogram, often as a screen for relatives of affected 
individuals.  One of the most characteristic features is hypertrophy of the 
myocardium, visualized as a thickening of the ventricular septum or wall (Maron 
et al. 1985; Maron et al. 1987; Maron et al. 2003a).   
Non-congenital cardiac hypertrophy, in most cases, is secondary to 
conditions that increase load on the heart, such as systemic hypertension or 
exercise.  Physiological hypertrophy seen in athletic individuals is an adaptive 
response, which is both reversible and maintains normal tissue architecture.  
Hypertrophy in response to diseases such as hypertension is initially an adaptive 
response, but eventually progresses to cardiac dysfunction and failure (Rose. 
2006).   
The idiopathic hypertrophy seen in HCM has a distinctive course, 
generally accompanied by fibrosis and myofibrillar disarray (Figure 1) (Seidman 
and Seidman. 2001).  Secondary messengers play a large role in gross 
pathological changes.  There is still debate over the particular pathways leading 
to the activation of these signals.  Angiotensin II is an important modulator, with 
some studies showing loss of hypertrophic response with angiotensin II 
knockdown (Lim et al. 2001).  Other signals such as atrial natriuretic peptide, 
protein kinase A and C have also been implicated.  These molecules are 
upregulated in response to the inefficient contraction of the heart, leading to 
cardiac remodeling (Marian and Roberts. 2001). 
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Figure 1.  (A)  Shows the normal architecture of myocardium with orderly pattern 
of myocytes and minimal fibrosis.  (B)  Shows histopathology of myocardium in 
HCM.  Cardiomyocytes are stained red and show disarray with significant fibrosis 
(stained blue).  Seidman et al. Cell 2001. 
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 Asymmetric ventricular septal hypertrophy is the most common 
presentation of HCM, though there are several morphological variants.   
Interstitial fibrosis contributes significantly to thickening of the ventricular septum.   
The hypertrophy can lead to left ventricular tract obstruction.  This disrupts the 
lamellar bloodflow along with increasing cardiac workload (Haber. 1995; Maron 
et al. 2003b).  All these changes are important in disease progression, but are 
secondary to the underlying pathology at the sarcomeric level.   
Treatment 
As the primary cause of disease remains poorly understood, the familial 
cardiomyopathies are currently treated symptomatically.  Due to a paucity of 
clinical trials, most treatment strategies are based on observational data (Fifer 
and Vlahakes. 2008).  Asymptomatic patients with high risk features may be 
treated, though the benefits are unclear.  The goal of managing  patients with 
cardiomyopathy is to reduce symptoms and improve the quality of life, but current 
medical management has not been shown to significantly alter disease 
progression and mortality (Maron et al. 2003a; Rose. 2006).   
 β−blockers remain the mainstay of current treatment for most cases, along 
with blockers of both calcium and sodium channels.  One of the major affects of 
hypertrophy is increased stiffness of the ventricular walls, leading to reduced 
relaxation during diastole.  These drugs reduce the heart rate and contractility, 
thereby relieving cardiac stress and improving diastolic filling.    The reduced 
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stress may relieve angina symptoms by reducing oxygen demand and possibly 
improving myocardial perfusion (Rose. 2006).   
Exercise restriction is also generally applied to all cases of HCM and RCM 
to reduce the risk of ventricular arrhythmias leading to sudden cardiac death.  In 
patients with propensity for arrhythmia, pacemakers are utilized to normalize the 
rhythm (Robinson et al. 1990). 
The only treatment shown to be effective in reversing the course of HCM 
is surgery, but this is reserved for patients with persistent symptoms or severe 
outflow tract obstruction.  Myomectomy has been used in refractory cases with 
good results, where a portion of the septum and ventricular wall are surgically 
removed (Morrow et al. 1975).  A newer method is alcoholic septal ablation, in 
which a percutaneous catheter introduces alcohol into the septum resulting in 
tissue death.  This is also an effective treatment, if administered in an institution 
with expertise in septal ablation (Kimmelstiel and Maron. 2004).  Surgery is not, 
however, recommended to the majority of cases as it carries its own inherent 
risks.  There is a small percentage of surgical mortality as well as deleterious 
effects on the myocardium.   
Surgical procedures, along with cardiac transplantation remain a last 
recourse for end stage patients, but a more general treatment requires a better 
understanding of the underlying cause of the disease at the sarcomeric level.  
The ideal treatment would involve gene therapy, removing the disease causing 
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mutation.  Currently gene therapy remains in the development stages, making it 
impractical for widespread use beyond early stage clinical trials.   
The immediate effect of these sarcomeric mutations is alteration of the 
regulation of cardiac muscle contraction.  Inefficient contraction leads to release 
of secondary messengers and the various pathological changes described 
above.  Treating the disease by reversing its deleterious effects on sarcomeric 
regulation would target the primary pathology underlying the remodeling of the 
heart.  This requires a more thorough understanding of cardiac muscle regulation 
and how this is altered by these mutations. 
Sarcomeric Regulation of Myocardium 
Muscle regulation is controlled by the proteins forming the sarcomere as shown 
in Figure 2 (Arad et al. 2002).  One of the major components of the sarcomere is 
the thin filament comprised of actin polymers organized in a helical structure 
along with the associated regulatory proteins tropomyosin and troponin.  
Tropomyosin is a long coiled-coil dimer that spans the length of seven actin 
protomers and forms a single regulatory unit.  The troponin complex binds to the 
actin-tropomyosin unit conferring calcium sensitivity.  This trimeric complex is 
composed of troponin C (TnC), I (TnI), and T (TnT).  The other major component 
is the thick filament which is formed by myosin bundles.  There are numerous 
other components such as myosin light chains, titin, and others which play a 
regulatory role, but we shall focus on the proteins outlined above. 
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Figure 2.  Diagram showing the thin and thick filaments with component 
proteins.  The main protein of the thin filament is actin which forms a helical 
filament while myosin forms the major component of the thick filament.  The main 
regulatory proteins of cardiac muscle are shown: tropomyosin, troponin C, I, and 
T.  Calcium is shown bound to troponin C.  Modified from Arad et al. Hum. Mol. 
Genet. 2002 
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Sliding Filament Theory of Muscle Contraction 
The prevalent theory of muscle contraction is based on the sliding of the 
thin and thick filaments past one another in a repetitive cycle.  The myosin heads 
bind and hydrolyze ATP.  The hydrolysis of ATP provides the energy for muscle 
contraction, and the rate of this hydrolysis is a key component to regulating 
muscle contraction (Chalovich. 1992; Chalovich. 2002).  Myosin undergoes 
several conformational changes during the various steps of hydrolysis, coupled 
with binding and release from the thin filament as the binding properties of 
myosin to actin are altered.  The power stroke occurs as the myosin is bound, 
moving the filaments; subsequent release and binding of myosin to actin allow 
this process to repeat.  This process underlies both skeletal and cardiac muscle 
contraction, and the rate and control of this process is highly dependent on the 
regulatory proteins troponin and tropomyosin (Chalovich. 1992; Gordon et al. 
2000). 
Regulatory Thin Filament Proteins 
Troponin.  The troponin complex provides calcium sensitivity to the 
sarcomere, providing the physiological control for muscle contraction.  Figure 3 
shows the crystal structure of the complex in the presence of calcium (Takeda et 
al. 2003).  Troponin C is the calcium binding subunit with four ion binding sites in 
skeletal muscle and three functional sites in cardiac muscle.  Two of these sites 
are bound by magnesium, leaving only one regulatory site for cardiac muscle.  
This subunit is composed of two globular heads joined by a helical domain.  On 
12 
 
 
 
 
 
 
Figure 3.  The crystal structure of the troponin complex in the presence of 
calcium.  Troponin C is shown in green.  Troponin I is shown in red.  Troponin T 
is shown in blue.  The inhibitory segment of troponin I has not been characterized 
and is shown schematically as a solid red bar.  The bordering amino acids of the 
uncrystallized segment are indicated.  Similarly the C-terminal end of Troponin I 
is not crystallized and the amino acid bordering this domain is indicated. The 
figure was prepared using the coordinates for crystal structure 1J1E with the 
program Pymol. 
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binding of calcium, a hydrophobic pocket becomes available for binding of 
troponin I (Herzberg and James. 1985; Slupsky and Sykes. 1995). 
Troponin I is the inhibitory subunit, which has the major inhibitory site on 
residues 128-147.  This site, when in contact with actin, reduces the ATPase rate 
of myosin, thereby resulting in relaxation.  Opening of the TnC hydrophobic 
pocket on binding of calcium attracts and binds the switch segment of TnI 
(Residues 147-163).  This moves the inhibitory segment away from actin, 
allowing contraction by increasing the ATPase rate.  Significant portions of TnI 
are disordered and poorly characterized with crystallography including the 
inhibitory segment and a C-terminal domain.  Both of these regions may become 
more ordered during binding to actin.  This disorder to order transition may assist 
in movement of TnI between the hydrophobic pocket of Tnc with calcium binding 
to the actin thin filament after calcium release.  The increased flexibility of these 
segments increases the range of motion available to the subunit (Filatov et al. 
1999; Vinogradova et al. 2005).  Disease causing mutations may alter this 
flexibility or the binding of the inhibitory region. 
Troponin T binds to troponin I, troponin C, tropomyosin, and actin.  It helps 
to tether the entire complex to the thin filament and also contains inhibitory sites.  
TnT allows the rest of the troponin complex to remain tightly bound to actin-
tropomyosin in the absence of calcium.  It is also essential for potentiation, which 
is an increase in ATPase rate over that of unregulated actin (Greaser and 
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Gergely. 1971; Ebashi. 1972).  This indicates that binding of troponin is 
necessary both for inhibition of ATPase rates and also to achieve the maximal 
rate by fully stabilizing the active state. 
Tropomyosin.  Tropomyosin is the other major regulatory protein on the 
thin filament.  This protein is a 400 Å long coiled coil that lies along the groove of 
the thin filament.  Its position on the filament is intimately related to the 
occupancy of calcium on the adjacent troponin complex and the presence or 
absence of tight binding myosin heads.  Being a longer protein than troponin, 
tropomyosin transmits the regulatory signal of calcium binding at least along the 
seven actin protomers it is bound to.  A normal thin filament will have repetitive 
units of tropomyosin lying end to end, providing cooperativity to the system.  The 
presence of tropomyosin also strengthens the binding of troponin (Eaton et al. 
1975).   
Alterations in the function of both troponin and tropomyosin will have a 
significant impact on the inhibition and activation of cardiac muscle, and several 
of the cardiomyopathy causing mutations are present on these two proteins.  Part 
of the goal of this project was to determine whether the mutations on 
tropomyosin have a similar impact on regulation as the ones on troponin.  This is 
not unlikely, as the entire actin-troponin-tropomyosin complex can be considered 
a single regulatory unit, all undergoing conformational changes on the binding 
and release of calcium to TnC and myosin to actin. 
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Models For Studying Cardiac Muscle Regulation 
Troponin and tropomyosin mutations causing cardiomyopathy often 
produce altered calcium sensitivity and hypertrophy in cardiac muscle.  By 
discovering the underlying mechanism of regulation that is altered by these 
mutations and relating it to a model of muscle contraction, we will better 
understand the pathology of HCM and other congenital muscle diseases.  These 
models are useful for determining the relationships between the different states 
of regulated actomyosin, and can simulate changes caused by disease causing 
mutations.   
Hill model.  The Hill model for muscle regulation was one of the earlier 
models for simulating muscle regulation incorporating the different substates of 
regulated actomyosin (Hill et al. 1980; Hill et al. 1981).  It describes a parallel 
pathway system, where the different states are all in equilibrium with each other.  
This is in contrast to a sequential system where the inactive state must go 
through intermediate states before it can reach the fully active state.  The 
distribution of states is determined by the environment and the regulatory 
proteins present on muscle filament.  This model has generally been described in 
the past with two states (Figure 4), although it is capable of incorporating any 
number of states.   
The muscle contraction cycle involves the hydrolysis of ATP as an energy 
source and the movement of myosin on the thin filament is intimately linked to 
the stages of phosphate cleavage and release.  The enzymatic ability of myosin 
17 
 
 
 
 
 
 
 
Figure 4.  Schematic showing the parallel pathway model for muscle 
regulation. Myosin must be bound to actin in the active state (Aa) for rapid 
hydrolysis of ATP. Actomyosin in the inactive state (Ai) does not hydrolyze ATP 
at a sufficient rate to drive muscle contraction and the enzymatic activity of 
unbound myosin is very low. Ca2+ partially shifts the equilibrium between states 
to favor the active state but cannot fully activate the filament  Tight binding forms 
of myosin or S1 (rigor myosin, myosin-ADP, NEM-S1) shift the equilibrium to the 
fully active state. Thus, alterations in troponin I could potentially alter the 
equilibrium between states, reduce myosin-ATP binding, or alter a step within the 
active pathway. 
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to cleave ATP is much higher when bound to actin in the active state than when 
bound to inactive actin or unbound.  Muscle contraction occurs when actomyosin 
is hydrolyzing ATP along the fast pathway with actin in the active state. 
In the absence of calcium or myosin, the actin is in the inactive state.  This 
state has minimal ATPase activity and is the predominant state in relaxed 
muscle.  When calcium binds to TnC, the resulting structural change shifts the 
inhibitory segment of TnI away from actin, and muscle activity is increased.  This 
partial activation shifts the equilibrium toward the active state, although there is 
still a significant amount of inactive state remaining.  Full activation requires 
binding of tight binding forms of myosin.  This shifts the equilibrium fully to the 
active state, allowing for maximal ATPase activity (Chalovich. 1992). 
So the overall activity of muscle filaments is an aggregate of the activity of 
the various states of regulated actin and the fraction of each state present.  As 
calcium and tight binding forms of myosin are added, there is a larger fraction of 
active state present, increasing the overall activity.  In the parallel pathway 
model, myosin can fully activate the thin filament in the absence of calcium.  
The Hill model is an allosteric model in which changes in activity are due 
to changes in structure of the sarcomeric proteins.  The regulatory proteins 
troponin and tropomyosin along with actin can be considered as one large 
cooperative unit.  Calcium binds to the TnC subunit of troponin, but this signal is 
transmitted along the entire filament through interactions passed along the 
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regulatory proteins.  The movement of the inhibitory segment on TnI is triggered 
by the opening of the hydrophobic pocket on TnC following calcium binding.  This 
movement of the TnI inhibitory segment away from actin causes a shift in the 
position of tropomyosin (Pirani et al. 2006).  Tropomyosin spans seven actin 
protomers, transmitting the calcium binding signal from the narrow troponin 
complex along the actin filament.  End to end interactions of tropomyosin allow 
for cooperativity between one regulatory unit of seven actin protomers, and 
adjoining units.  Once one unit is activated, it is easier to active neighboring units 
(Butters et al. 1993). 
We have used two states in the past to describe regulation, as this was 
the simplest system that was capable of defining the data (Gafurov et al. 2004a; 
Gafurov et al. 2004b; Mathur et al. 2008).  An increase in the number of states 
would, of course, still be able to simulate the results.  Structurally, three states 
have been demonstrated by crystallography and computer reconstructions 
(Lehman et al. 2000; Pirani et al. 2005; Pirani et al. 2006).  This is not 
necessarily an indication of three functional states.  This project examined 
several mutations of troponin and tropomyosin to determine if they could also be 
evaluated using two states or if a third intermediate state was necessary.   
Models are useful in examining the data in terms of affects of mutations on 
regulation.  There are several steps along which a cardiomyopathy causing 
mutation could alter the activity of muscle filaments.  As the majority of 
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contraction occurs when actin is in the active state, a reduction or increase in the 
activity of this state would have a significant impact on contraction.  Second, the 
contraction cycle requires the binding of myosin leading to ATP hydrolysis.  A 
change in the binding of myosin due to the mutation would alter the number of 
myosin heads available for ATP hydrolysis.  Finally, a shift in the equilibrium 
between states would alter the regulation and activity.  A shift to active state 
would increase the activity, while a shift to the inactive state would reduce it.  
Analyzing ATPase rates, S1 binding in ATP and ADP, and activation of ATPase 
activity by Ca++ and myosin will help determine which step is altered by the 
various mutations.   
Other Models.  It is important to recognize that other models of regulation 
exist.  The McKillop and Geeves model and the Tobacman model are two 
examples (McKillop and Geeves. 1993; Tobacman and Butters. 2000; Smith and 
Geeves. 2003).  The Geeves model is a well recognized composite of a steric 
blocking model and an allosteric model with three states.  One key difference 
between this model and the Hill model is the assumption that tropomyosin blocks 
the binding of myosin to actin in the inactive state, resulting in inhibition of activity 
as opposed to inhibition being due to allosteric changes.  Another difference is 
the sequential nature of this model.  There are three states: blocked, closed, and 
open.  The inactive blocked state must be activated by calcium and enter the 
closed state before tight binding forms of myosin can shift the closed state to the 
open state.  The open state is the only state which has any activity, whereas in 
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the Hill model both states have some activity.   
The Geeves model is a modification of the Hill model that was developed 
due to perceived problems with the latter system.  However, these perceptions 
have turned out to be incorrect and the Hill model is able to account for the 
effects of Ca2+ on equilibrium binding of myosin to actin, the rate of binding of 
myosin to actin and the steady-state ATPase activity (Chalovich et al. 1981; 
Chalovich and Eisenberg. 1982; Chalovich. 1990; Chalovich. 1992; Chalovich. 
2002; Gafurov et al. 2004a; Gafurov et al. 2004b).  In fact, only the Hill model has 
been shown to be able to predict ATPase rates correctly. 
Finding the Primary Defect in Regulation 
Group Mutations Into Categories 
The overall goal of the project is to examine several cardiomyopathy 
causing mutations of troponin and tropomyosin to determine if a common 
mechanism is responsible for this disease.  Due to the cooperativity of the 
system, and previous evidence that the equilibrium between states is important in 
regulation, it was likely that a large set of mutations may share a common effect 
in shifting the distribution between actin states.  By studying several mutations it 
is possible to further asses the various models of regulation along with the 
individual regulatory states.  A better understanding of sarcomeric regulation and 
the effects of the mutations on this process will provide a better target for 
therapy.   
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Using Physiological Modifications to Reverse Pathology of Cardiomyopathies 
Examination of physiological modifications such as protein kinase C (PKC) 
phosphorylation of TnI, which have opposite effects to some cardiomyopathy 
mutations in functional assays, provides a means to reverse the disease using 
preexisting signaling mechanisms.  Utilizing an endogenous pathway would 
reduce the risk of complications due to medical therapy.  Ideally the physiological 
modification would alter the same step as the mutations, but in the reverse 
manner.  We have analyzed PKC phosphorylation and cardiomyopathy causing 
mutations in order to compare their effects on the regulatory mechanism.  First 
we will detail the properties of PKC phosphorylation of TnI. 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER II:  PROTEIN KINASE C PHOSPHORYLATION OF TROPONIN I 
STABILIZES THE INACTIVE STATE OF ACTIN 
Introduction 
Reversible modifications of the regulatory proteins troponin and 
tropomyosin alter the function of sarcomeric proteins as part of physiological 
adaptation.  These responses are seen in cases of exercise, normal myocardial 
adaptation to increased load, and also in response to pathological states such as 
hypertension and hypertrophy leading to cardiac remodeling.  These responses 
may be modified for utilization as therapeutic targets in cases of defective 
regulation.  This is especially the case if these modifications affect the distribution 
of actomyosin states in an opposite manner to that seen with cardiomyopathies.   
Our goal is to determine whether an important physiological modification, 
protein kinase C phosphorylation of troponin I, stabilizes the inactive state of 
troponin.  This would become a useful tool for treatment in the case of 
cardiomyopathies which stabilize the active state of actin such as the Δ14 
mutation on troponin T.  Functional studies outlined below indicate that PKC 
phosphorylation may stabilize the inactive state. 
Protein Kinase C Characteristics 
Phosphorylation of troponin I occurs in normal and failing hearts, and is 
still not fully understood despite in vivo and physiological studies (Node et al. 
1997; Rose. 2006; Belin et al. 2007).  Both Protein kinases A and C have 
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significant activity in the heart.  In vivo studies show an elevated level of PKC in 
end stages of cardiomyopathy.  This may either be an adaptive response to the 
cardiac remodeling and altered regulation due to the disease causing mutations, 
or it may be a contributing cause of cardiomyopathy.  Phosphorylation has been 
demonstrated to decrease contractility and calcium sensitivity of myofilaments 
(Burkart et al. 2003; Finley and Rosevear. 2004). 
Protein kinase C acts downstream of Gq and G11 pathways as a 
response to biomechanical stress or neurohormonal mediators.  The major 
stimulants of these pathways are α-adrenergic hormones, angiotensin II, and 
endothelin-1.  About 12 PKC isoforms have been reported so far and they are 
classified into three subsets by their activation mechanisms: conventional, novel, 
and atypical.  Conventional PKCs require calcium, phosphatidylserine  and 
diacylglycerol for activation.  Novel PKCs do not require calcium for activation 
and atypical PKCs require neither calcium nor diacylglycerol.  The four most 
functionally relevant isoforms in the heart are PKC α and β from the conventional 
type and δ and ε from the novel type (LaMorte et al. 1994; Jideama et al. 1996; 
Dorn and Force. 2005).   
Levels of the cardiac specific isoforms of PKC are dependent on the 
developmental stage and cell type.  The activity of each isoform is dependent on 
quantity expressed, localization and its phosphorylation state.  Multiple isoforms 
are upregulated in hypertrophy of the heart and have overlapping effects.  Adding 
a further layer of complexity, several isoforms interact and regulate each other 
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within the heart (Dorn and Force. 2005).  This makes it more difficult to analyze 
the importance of specific isoforms in hypertrophy.  PKC α and β are generally 
accepted as being the two most important isoforms to be activated in hypertrophy 
and heart failure. 
Inactive forms of PKC are generally localized within the cytosol and need 
to be transported to the cell membrane which is the location of their hydrophobic 
activators.  PKC is spatially organized within the cardiomyocyte, with different 
isoforms present in different areas.  For example, PKCβ is located near fibrillar 
structures within the cardiomyocyte when inactive, and is transported to the 
perinucleus and cell periphery when activated.  The localization and control of 
activation is dependent on binding proteins that are specific to each isozyme.  
RICKs (receptors for inactivate C kinase) bind inactive PKCs while RACKs 
(receptors for active C kinase) bind active PKCs.  These proteins colocalize with 
their respective PKC in cells (LaMorte et al. 1994; Dorn and Force. 2005). 
Protein Kinase C Appears to Stabilize the Inactive State 
Several functional properties indicate that PKC phosphorylation of TnI 
could be a therapeutic target in treating HCM.  In physiological studies, the 
phosphorylated proteins shifted many functional properties towards a more 
inhibited state.  Troponin I mutants mimicking constitutive phosphorylation were 
exchanged into skinned muscle fibers to determine changes in function.  The 
altered myofibrils showed a reduced sensitivity to calcium in producing force 
(Burkart et al. 2003).  They also showed a reduction in calcium sensitivity during 
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in vitro motility assays along with a reduced maximal sliding velocity.  These 
results give an indication of enhanced inhibition of activity (Burkart et al. 2003).  
However the underlying mechanism of altering muscle regulation was not clearly 
elucidated.  This is important because several previously studied HCM causing 
mutations such as Δ14 and R92Q on TnT have been shown to enhance activity 
(Gafurov et al. 2004b).  If the regulatory step that is inhibited by PKC 
phosphorylation of TnI is identical to the step that is enhanced by HCM causing 
mutations, PKC can be targeted as a inherent therapeutic target to reverse the 
changes seen in cardiomyopathy. 
Phosphorylation Sites on Troponin I Specific For PKC 
The phosphorylation sites specific for PKC on troponin I are Ser-42, Ser-
44, and Thr-143 (Human sequence).  Each isoform of PKC may have different 
predilections for phosphorylating the three sites of TnI. Some isoforms of PKC 
also phosphorylate residues 22 and 23, which are the normal protein kinase A 
phosphorylation sites of troponin I. Several studies, including those with 
transgenic animal models, treated residues 42 and 44 as a cluster and indicated 
that the phosphorylation of residues 42 and 44 has a large impact on 
myofilament activity.  Finley and Rosevear showed that the introduction of 
negative charges into these two sites destabilized helix G of the C-lobe of cardiac 
troponin C in the troponin C-troponin I binary complex (Finley and Rosevear. 
2004).  Ruse et al. found that of these two residues only Ser-45 was 
phosphorylated when they treated isolated cardiac troponin I with PKC (Ruse et 
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al. 2002).   
Target Residues for PKC Are Located In Important Troponin I Domains 
Figure 5 shows the locations of residues 42, 44 and 143 in a schematic 
diagram of the core domain of cardiac troponin.   
Thr-143 is located in the middle of the inhibitory region of cardiac troponin 
I, which connects the regulatory head to the IT arm and is not visible in the 
crystal structure of the cardiac troponin core domain.  This domain plays an 
important role in muscle regulation.  In the absence of calcium the inhibitory 
segment is bound to the actin filament, preventing actin activation of hydrolysis of 
ATP by myosin.  In the presence of calcium the inhibitory segment detaches and 
moves away from the thin filament.  Because of the location of Thr-143 in this 
domain, modification of this residue could affect the myofilament activity, 
especially in the resting state where it could alter its binding capabilities. Some 
studies showed the functional importance of the phosphorylation of Thr-143 by 
demonstrating the reduction in calcium sensitivity and prolongation of muscle 
relaxation time (Westfall et al. 2005; Wang et al. 2006).   
Residues 42 and 44 are located in the IT arm region and are close to the 
C-lobe of cardiac troponin C.    This lobe of TnC is tightly bound to TnI in both the 
absence and presence of calcium.  The impact of these two phosphorylation 
sites on activity has not been fully elucidated, and will be studied in our work. 
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Figure 5.  Schematic structure of the troponin complex in the absence (A) 
and presence (B) of calcium.  Troponin C is shown in black, troponin I in green 
and troponin T in grey.  The structure of residues 31 to 163 have been resolved 
for TnI and residues 183 to 288 are shown for TnT.  (A)  The troponin complex in 
the absence of calcium shows a more ordered inhibitory segment on TnI and a 
closed hydrophobic pocket on TnC.  The structure in the absence of calcium is 
based on the crystal structure of skeletal troponin.  The switch segment is 
assumed to be a helix in the absence of calcium (diagonal shading) as described 
in Vinogradova et al. PNAS 2005.  The PKC sites are on the TnC binding region 
and the inhibitory segment (shown as a single red circle for the approximate site 
of residues S42 and S44 and a red circle for residue T143).  (B)  The complex in 
the presence of calcium showing a more disordered inhibitory segment and 
binding of the switch segment to troponin C.  Many of the disordered regions 
have not yet been resolved with crystallography. 
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Phosphorylation Mimicking Mutations 
We began our examination with mutants mimicking protein kinase C 
(PKC) phosphorylation of troponin I.  Previously we had shown that the Δ14 
mutation of TnT caused a stabilization of the active state.  Unpublished work 
from our laboratory showed a similar result with the R92Q mutation on TnT.  Our 
hypothesis being that this shifting of the equilibrium between the inactive and 
active states was important in causing cardiomopathy, we wished to determine 
whether a similar mechanism applied to a physiological modification such as 
PKC phosphorylation.  The functional assays outlined above indicate that PKC 
inhibits the activity of the thin filament, stabilizing the inactive state.  The 
experiments detailed in the results below were conducted to prove that the 
inactive state is indeed stabilized by PKC phosphorylation on TnI. 
Dr. Kobayashi produced a constitutive model of phosphorylation by 
mutating the PKC sites to glutamate.  These mutations have been shown to have 
similar properties as modification of TnI with PKC in terms of inhibiting calcium 
activation of thin filaments and inhibiting ATPase rates (Burkart et al. 2003).  We 
used an expressed mouse troponin complex with corresponding residues being 
S43 (human S42), S45 (human S44), and T144 (human T143).  The three 
mutations used were S43E/S45E, S45E, and S43E/S45E/T144E.  
Phosphorylation of residues 43 and 45 have been shown to significantly alter 
calcium sensitivity, but the effect of 45 alone has not been rigorously examined. 
(Montgomery et al. 2002; Pyle et al. 2002; Burkart et al. 2003).  Using the 
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combination of mutations listed, we would be able to determine whether 
alteration of residue 45 was sufficient by itself to stabilize the inactive state or 
whether the other two sites were also required for maximal effect.  
Results 
ATPase Rates in the Absence of Significant Myosin Binding 
We began by examining the ATPase rates in the presence and absence of 
calcium for wild type troponin and for mutants that simulate phosphorylation at 
various sites.  We would expect that in the case of inhibition these rates would be 
reduced in the presence of calcium.  In the absence of calcium, the rates might 
already be fully inhibited, and so further inhibition would not be detected.  The 
rates were collected during the initial phase of hydrolysis, during which there is a 
linear release of inorganic phosphate with ATP in excess (1mM ATP with 10μM 
actin and 0.1μM S1).   
Figure 6 shows that in the presence of Ca2+ all of the mutants had 
repressed ATPase rates relative to wild type (p < 0.05).  The rates in the 
presence of calcium were: Wild type 1.26 s-1, S45E 0.38 s-1, S43E/S45E 0.37 s-1, 
and S43E/S45E/T14E 0.30 s-1.  The values represent the mean of six repetitions.   
Calcium alone is sufficient only for a partial shift to the active state.  It 
appears then that PKC phosphorylation represses the ability of actomyosin to be 
activated by calcium.  The introduction of a single negative charge at position 45 
was sufficient to reduce the Ca2+ activated ATPase rate.  It was interesting to 
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Figure 6.  Inhibition of actin-activated ATPase activity by mutants in both 
the presence (solid bars) and absence (light bars) of Ca2+ at 0.05 M ionic 
strength.  Initial velocities in units of μM ATP/sec/μM S1 are shown for wild type 
cardiac troponin and the following mutants: S45E, S43E/S45E and 
S43E/S45E/T144E.  All rates were corrected for the ATPase rate of S1 in the 
absence of actin. Data are presented as mean values ± s.d (n = 6). Conditions: 
25oC, pH 7, 0.1 μM S1, 10 μM actin, 1 mM ATP, 10 mM MOPS, 3 mM MgCl2, 33 
mM NaCl, 1 mM dithiothreitol, 0.5 mM CaCl2 or 1 mM EGTA. 
Actin:tropomyosin:troponin is 7:1.5:1.5.  
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note that the S45E mutation reduced the rate to around the same velocity as the 
S43E/S45E or S43E/S45E/T144E mutations.  Ratios of the ATPase rates (wild 
type/mutant) were: 3.3 for S45E, 3.4 for S43E/S45E, and 4.2 for 
S43E/S45E/S144E.   
No significant differences were observed between the wild type and the 
mutations in the fully inhibited state where EGTA was added to sequester the 
free Ca2+.  The mean rates were: Wild type 0.32 s-1, S45E 0.27 s-1, S43E/S45E 
0.26 s-1, and S43E/S45E/T144E 0.21 s-1.  The differences in rate all fall within the 
margin of error with p > 0.05.  In the absence of calcium the thin filament is 
almost entirely in the inactive state.  In this case, it would not be unlikely that we 
would see little to no change even if protein kinase C phosphorylation has an 
inhibitory effect.  As the wild type is largely inactive, and the rates are very low, 
any further shift would likely be too small to be detected within the error of 
measurement. 
Phosphomimetics at sites 43, 45, and 144 inhibit ATPase activities in the 
presence of calcium.  We suggest that these mutants stabilize the inactive state 
of actin.  That is, these mutations have the opposite effect as the Δ14 mutant 
which causes cardiomyopathy.  These experiments were conducted with low 
concentrations of S1 (0.1μM) compared to the actin concentration.  As a result, 
there is an insufficient concentration of S1 to fully activate the thin filament.  The 
thin filament is almost completely in the inactive state in the absence of calcium, 
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and only partially activated in the presence of calcium.  In later experiment we 
will examine the effects of these mutations when the filament is fully activated. 
 Myosin-ADP Binding Indicates Stabilization of Inactive State 
 One way of probing the distribution between inactive and active 
states is by an analysis of binding of S1-ADP to actin-tropomyosin-troponin.  
Light scattering measurements allow us to examine cooperative binding curves 
of myosin to actin (Figure 7).  Unlike myosin-ATP, which binds equally to actin in 
the active and inactive states, myosin-ADP binds preferentially to the active 
state.  It is also capable of shifting the inactive state completely to the active 
state.  Figure 7 shows a series measuring light scattering with increasing free S1-
ADP concentrations in the absence of calcium.  In these experiments the filament 
began in the inactive state.  The addition of a tight binding form of mysosin, 
myosin-ADP, gradually shifted the equilibrium to the active state.  The binding 
profiles were more sigmoidal for the mutants, requiring a higher concentration of 
free S1-ADP to reach a similar fraction of total light scattering.  This more 
pronounced “S” shape with a greater lag at low concentrations of free S1-ADP is 
indicative of stabilization of the inactive state of actin.  The lag of binding is 
noticeably greater with the phosphomimetic mutations than with wild type.   
NEM-S1 Activation of Thin Filament Shows No Alteration of Maximal Rate 
The relative stabilities of the inactive and active states at any condition 
can be measured by the degree of activation of ATPase activity relative to the  
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Figure 7.  Representative curves showing binding of S1-ADP to actin-
tropomyosin-troponin in the absence of Ca2+ at 120 mM ionic strength.  
Binding curves for each mutant were repeated 3-4 times.  (A) shows the binding 
of WT (circles) and mutant 45 (squares) with increasing S1-ADP concentrations, 
(B) shows WT (circles) and mutant 43/45 (squares), (C) shows WT (circles) and 
mutant 43/45/144 (squares). Insets show saturation, x-axis: [S1-ADP]Free (0 to 1 
μM), y-axis: ActinBound/ActinTotal (0 to 1.1).  Conditions: 25oC, pH 7, 0.075 μM 
phalloidin-actin, 0.2 mg/mL BSA, 14 units/mL Hexokinase, 1 mM Glucose, 20 uM 
AP5A, 2 mM ADP, 20 mM MOPS, 5 mM MgCl2, 88 mM NaCl, 1 mM dithiothreitol, 
1 mM EGTA.  Actin:tropomyosin:troponin was 1:1:1.  Light Scattering was used 
to measure the binding with excitation at 340 nm and emission at 360 nm.   
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fully inactive state (EGTA, no strongly bound S1) and to the fully active state 
(either Ca2+ or EGTA with optimal amounts of strongly bound S1).  NEM-S1 is a 
modified S1 which binds to actin but has minimal ATPase activity and therefore 
serves as a tool to stabilize the active state of actin.  The ATPase activity of a 
small amount of unmodified S1 (0.1 μM) gives a measure of the degree of 
activation of the actin thin filament.  The NEM-S1 concentration was increased 
until the ATPase rate began to plateau.  The binding of unmodified S1 is not 
altered with increased binding of NEM-S1 as the actin concentration was also 
correspondingly increased to maintain a constant amount of free S1. 
Figure 8 shows the results of the NEM-S1 dependent acto-S1 ATPase 
activities in the presence of Ca2.  Without NEM-S1, the ATPase rates of the 
mutants were 24-30% of the wild type values.  However, at intermediate 
concentrations of NEM-S1 (i.e. 2 μM NEM-S1) the ATPase rates of the 3 mutants 
and the wild type began to converge (Fig. 8 A-C).  At high concentrations of 
NEM-S1, the rates were nearly identical indicating that all troponin types 
examined produced the same maximum rate.  This convergence of rates is easily 
seen in Fig. 8D which shows the ratio of ATPase rates as a function of NEM S1 
concentration for each of the mutants.  The ratio of rates (mutant/wild type) 
tended to converge to 1 with increasing concentrations of NEM-S1 for all of the 
mutants.  At 2 μM NEM-S1, the effects of the single mutation at position 45 were 
reversed to a greater extent than the other mutants.  However, at 7 μM NEM-S1,  
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Figure 8.  Actin-activated ATPase activity of S1 with increasing 
concentrations of activating NEM-S1 in the presence of Ca2+.  The transition 
of the regulated acto-S1 complex to maximal ATPase activity with NEM-S1 
binding was blunted with the mutants.  (A) shows the rates of mutant 45 (dark 
bars) and WT (light bars) with increasing NEM-S1 concentration, (B) shows 
mutant 43/45 (dark bars) and WT (light bars), (C) shows mutant 43/45/144 (dark 
bars) and WT (light bars).  All rates were corrected for the ATPase rate of S1 and 
NEM-S1.  (D) shows the ratio between the mean rates of the various mutants to 
the wild type with (mutant 45)/(WT), (mutant 43/45)/(WT), and (mutant 
43/45/144)/(WT) at different NEM-S1 concentrations (0, 2, and 7 μM).  Data for 
A, B and C are presented as mean values ± s.d with the number of trials in 
parentheses.  Conditions: 25oC, pH 7, 0.1 μM S1, 10 μM actin, 1 mM ATP, 10 
mM MOPS, 3 mM MgCl2, 33 mM NaCl, 1 mM dithiothreitol, 0.5 mM CaCl2.  Actin 
concentration was increased by an amount equal to the NEM-S1 added to 
maintain the same free actin concentration.  Actin:tropomyosin:troponin is 
7:1.5:1.5. 
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the effect of the triple mutant was most completely reversed.  Thus the 3 
mutations showed minor differences but overall behaved similarly.   
 As shown earlier in Fig. 6, no significant difference was seen between any 
mutant and wild type in the absence of both Ca2+ and NEM-S1 (p > 0.05).  One 
reason for a lack of inhibition in EGTA is that the ATPase activity was already 
near its lowest possible rate in the case of wild type troponin.  To ascertain 
whether the depression of ATPase rates also occurred in the absence of Ca2+, 
we examined the effect of partial activation with NEM-S1.  Figure 9 shows that 
while the ATPase rates were similar in the absence of NEM-S1, the rates were 
lower for the phosphorylation mimicking mutants in the presence of NEM-S1 (p < 
0.05 for NEM-S1 = 4 μM).  These differences increased as more NEM-S1 was 
added.  Thus, the introduction of negative charges at positions 43, 45 and 144 of 
cardiac troponin stabilized the inactive state of regulated actin in both the 
presence and absence of Ca2+.   
It was not possible to reach saturating concentrations of NEM-S1 in the 
absence of calcium.  As the filament begins in the inactive state, a large amount 
of NEM-S1 is required to fully activate the filament.  At these high concentrations 
of NEM-S1 the corrections required become very large and introduce errors 
larger than the difference seen between the wild type and mutations.   
Calcium Binding to Troponin C is Reduced 
Ca2+ activates thin filaments because it binds more tightly to the active  
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Figure 9.  Actin-activated ATPase activitiy in the absence of Ca2+ with 
increasing concentrations of NEM-S1.  (A) shows the rates of mutant 45 (dark 
bars) and WT (light bars), (B) shows mutant 43/45 (dark bars) and WT (light 
bars), and (C) shows mutant 43/45/144 (dark bars) and WT (light bars).  (D) 
shows the ratio of mean ATPase rates with (mutant 45)/(WT), (mutant 
43/45)/(WT), and (mutant 43/45/144)/(WT) at different NEM-S1 concentrations 
(0, 0.5, 1, 4 μM).  All rates were corrected for the ATPase rate of S1 and NEM-
S1.  Data for A, B and C are presented as mean values ± s.d with the number of 
trials in parentheses.  Conditions: 25oC, pH 7, 0.1 or 0.2 μM S1, 10 μM actin, 1 
mM ATP, 10 mM MOPS, 3 mM MgCl2, 33 mM NaCl, 1 mM dithiothreitol, 1 mM 
EGTA.  Actin concentration was increased by an equal amount as the NEM-S1 
added to maintain the same number of binding sites.  Actin:tropomyosin:troponin 
is 7:1.5:1.5. 
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state of thin filaments and produces the conformational changes that activate 
ATP hydrolysis (It will also bind more tightly to the intermediate state if present).  
Thus, one would expect that mutations of troponin I that stabilize the inactive 
state should weaken Ca2+ binding.  Dr. Kobayashi’s lab measured the Ca2+ 
affinity for the mutants S45E and S43E/S45E/T144E along with the wild type 
ternary troponin complex using the fluorescence of an IAANS probe on troponin 
C (Fig. 10).  The normalized data shows reductions in calcium affinity for the 
troponin complexes with phosphorylation mimicking mutations as compared to 
wild type (p < 0.0001).  The association constants ± s.d. for Ca2+ of the troponin 
complexes were: wild type Ka = 5.45 ± 0.10 x 106 (M-1), S45E Ka = 2.12 ± 0.04 x 
106 (M-1), S43E/S45E/T144E Ka  = 1.76 ± 0.01 x 106 (M-1).  The S45E mutation 
was sufficient for producing most of the observed effect on Ca2+ affinity.  Note 
that the affinity was not reduced to such an extent that full Ca2+ binding under the 
conditions of Figs. 6 or 8 would be prevented.   
S1-ATP Binding to Actin Unaffected By Phosphomimetics 
Reduced binding of S1 to regulated actin during steady-state ATP 
hydrolysis could also cause a decreased activation of ATPase activity by actin.   
S1-ATP binds with equal affinity to actin in the active or inactive states.  Figure 
11 shows that the amount of S1 bound to actin during ATP hydrolysis was similar 
for wild type and all mutants at both 20 and 30 μM actin.  Therefore, differences 
in binding could not have explained the observed differences in activation of 
ATPase rates.    
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Figure 10.  Binding of calcium to various troponin complexes including 
wild type (circles), mutant 45 (squares), and mutant 43/45/144 (triangles).  
Binding was decreased for both mutants (n = 3-4).  The conditions were 100 mM 
NaCl, 5 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol and 20 mM MOPS, pH 7.0 
and the titration was carried out at 25oC. (Courtesy of Dr. Kobayashi) 
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Figure 11.  Effects of troponin I mutations on binding of S1 to actin in the 
presence of ATP.  Mean values of the fraction of S1-ATP bound with different 
actin concentrations at 0.04 M ionic strength are shown  ± s.d (n = 3).  Binding 
Conditions:  25 oC, pH 7, 0.1 μM S1, 3 mM ATP, 10 mM MOPS, 5 mM MgCl2, 14 
mM NaCl, 1 mM dithiothreitol, 0.5 mM CaCl2.  There was no significant difference 
in binding between the wild type and mutants at the actin concentrations 
measured. 
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Discussion 
Protein Kinase C Phosphorylation of TnI Stabilizes the Inactive State 
Our results clearly show an inhibitory effect on thin filament activity with 
the phosphorylation mimicking mutants as compared to wild type.  There was a 
3-5 fold reduction in the ATPase rate in the presence of calcium.  With activation 
by NEM-S1, there was a reduction in both the presence and absence of calcium.  
Here we have conducted several experiments, which in combination show that 
PKC phosphorylation of TnI inhibits cardiac muscle activity by shifting the 
equilibrium between actomyosin states towards the inactive state. 
 Examining the data in terms of the Hill model for regulation can 
systematically rule out different possible mechanisms of action.  First, muscle 
contraction occurs when actin is in the active state.  This state has maximal 
ATPase activity, which provides the energy for contraction.  An alteration in the 
rate of this pathway would alter muscle regulation by changing the ATPase rate.  
The rate of this pathway could be altered by inhibiting the rate limiting step.  This 
mechanism would show an altered ATPase rate even at high concentrations of 
NEM-S1 and no significant alteration in S1-ADP binding.  In contrast, the PKC 
phosphomimetic mutants showed similar ATPase rates to wild type at high NEM-
S1 concentrations and a lag in S1-ADP binding. 
A second possibility is that the mutations alter the binding of myosin to the 
thin filament during ATP hydrolysis.  Myosin’s enzymatic rate is only significantly 
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active when it is bound to actin.  A reduction in binding would inhibit the 
contraction cycle.  This was directly measured by ultracentrifugation to determine 
the fraction of S1-ATP binding, and no significant difference was seen with any of 
the mutants. 
The remaining major possibility is a shift in the equilibrium between states.  
The overall activity of the filaments depends on the fraction of each state present 
and the individual rate of each unique state.  So a shift in distribution towards the 
inactive state would reduce the overall rate, inhibiting the activity.  A shift in the 
opposite direction would activate the filament and increase the rate.  If this is the 
mechanism of action, there would be no difference in ATPase at high 
concentrations of NEM-S1 and a shift in binding of S1-ADP. 
As detailed in the results section above, our data clearly show a 
stabilization of the inactive state for the PKC phosphomimetic mutations.  The 
decrease in ATPase rate in the presence of calcium as compared to wild type 
gives an overall indication of inhibition.  The results with the addition of NEM-S1, 
are a strong indication of a shift in equilibrium towards the inactive state.  In the 
presence of calcium, the rates for the wild type and the mutants converge as the 
concentration of NEM-S1 is increased.  The individual pathways, inactive and 
active, remain unaltered, with only the distribution between states changing 
towards the inactive state.  As NEM-S1 is added, this equilibrium is again forced 
to the active state.  At high concentrations of NEM-S1, where the active state is 
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the only state present, the differences in overall rate between the wild type and 
mutations should be absent, as seen with the data.   
The results in the absence of calcium also strongly indicate a shift in the 
equilibrium.  In the absence of calcium with no NEM-S1, the predominant state is 
the inactive state and no significant difference is seen between wild type and the 
three mutants.  As the filament is partially activated with NEM-S1, the rates begin 
to diverge.  This indicates an altered distribution of active and inactive states 
resulting in a lowering of the overall rate with the mutants.  We could not reach 
fully activating conditions with NEM-S1 in the absence of calcium.  Our 
expectation is that at higher concentrations, the rate would again begin to 
converge as the active state became more predominant. 
 To confirm that the shifting of equilibrium was the step being altered, we 
measured the myosin-ADP binding which preferentially binds the active state.  
Our results showed a increased lag in binding, indicating a stabilization of the 
inactive state.  Although the differences were small, they were seen with all three 
mutants.  This data along with the NEM-S1 ATPases are a strong indicator that 
the inactive state is stabilized with mutations mimicking constitutive 
phosphorylation of TnI.  We ruled out the second possibility of a reduction in 
myosin-ATP binding by measuring binding affinities.   
 Finally, we used calcium binding to determine a shift in equilibrium.  
Calcium binds with a higher affinity to the active state, so stabilization of the 
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inactive state should shift towards a lower pCa++50.  This was seen with the data 
collected in Dr. Kobayashi’s laboratory.  So the combination of NEM-S1 
ATPases, S1-ADP binding, and calcium binding show that the mutations stabilize 
the inactive state of actin. 
Two States Sufficient to Explain Data 
 We used a two state model to simulate the results, which was sufficient to 
explain the data.  It is always possible to simulate the data with any number of 
states above this, but as a rule the simplest model should be used.  We have 
previously been able to simulate the results for the Δ14 and R92Q mutations 
using only two states (Gafurov et al. 2004b).  In those cases the active state was 
stabilized.  PKC phosphorylation alters the same step, the equilibrium between 
states, as the HCM mutations.  The former stabilizes the inactive state while the 
two HCM mutations stabilize the active state.  We would predict that a 
combination of the two should bring the HCM mutations activity closer to the 
activity of wild type. 
A Single Mutation At S45 Is Sufficient For Maximal Effect 
 It was interesting to note that the single mutation at the S45 site had 
generally the same effect as the double or triple mutations S43E/S45E and 
S43E/S45E/T144E.  It may be the case that residue 45 is the only significant 
residue, but confirming this would require studying single mutations at the other 
two sites.  Any one of the residues may be sufficient for full activation.  Data from 
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other labs, however, indicates that a mutation on residue 144 alone is not 
sufficient to change regulation. 
The Equilibrium Between States Is An Important Regulatory Step 
 The results from this study, along with previous work from our lab, indicate 
that the equilibrium between states plays a key role in normal and pathological 
muscle regulation.  It has been shown that disease causing mutations alter this 
equilibrium and now we have shown that a physiological modification acts on the 
same step.  We were interested in examining whether this important step is 
altered in other cardiomyopathy causing mutations, and whether they could also 
be analyzed with the same two step parallel pathway model.  This would allow us 
to begin to classify mutations by their underlying mechanism of action, pointing 
the direction towards a therapy aimed at the primary pathology. 
 
 
 
 
  
CHAPTER III:  SOME CARDIOMYOPATHY CAUSING MUTATIONS STABILIZE 
THE INTERMEDIATE STATE OF REGULATED ACTOMYOSIN 
Introduction 
Both the pathological condition of hypertrophic cardiomypathy and the 
physiological modification of phosphorylation of TnI have been shown to alter 
regulation by shifting the equilibrium between states.  Our studies so far have 
shown that cardiomyopathy causing mutations stabilize the active state and PKC 
phosphomimetic mutations have the opposite effect (Gafurov et al. 2004b; 
Mathur et al. 2008).  Both these conditions lead to secondary pathological and 
adaptive cardiac remodeling.   
There are approximately 60  mutations of troponin that cause 
cardiomyopathy, and we we were interested in determining if the equilibrium 
between states was a common mechanism by which they altered cardiac muscle 
regulation.  Due to the cooperative nature of thin filament regulation, the various 
sarcomeric proteins interact intimately and can be considered a single regulatory 
unit.  It is likely in this situation that a large number of mutations would have a 
similar effect on altering regulation.  Our previous results have indicated the 
significance of the distribution of states.  Although a comprehensive analysis of 
all mutations is beyond the scope of this project, defining the mechanism of 
action of several cardiomyopathy causing mutations is sufficient to show that this 
equilibrium could be a target for reversing the disease process at the primary 
defect in muscle regulation.
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Confirm Generality of Altering Distribution Between Two States 
Two states sufficient for previous mutants.  The previously examined 
mutations, Δ14 and R92Q, on TnT had shown enhanced activity and a shift in 
equilibrium from the inactive to active state.  It was possible to simulate the data 
for these mutations using a model with two states.  We were also able to explain 
the results of protein kinase C phosphorylation of TnI using the two state Hill 
model.  We started our examination of further cardiomyopathy causing mutations 
using two states, expecting to find that other cardiomyopathy causing mutations 
could also be explained using this system.  However, during the course of our 
study we found that although two states had sufficed in the past to simulate the 
data, several of the mutations studied showed a more complex behavior.  The 
data are detailed in the results section, but it is important to understand some of 
the differences between a two state model and three state model to fully 
comprehend the impact of these findings.  This is described below. 
Structurally there are three states.  Structural studies have persuasively 
shown that there are three states for regulated actomyosin.  These studies 
include x-ray crystallography, electron microscopy, FRET, and atomic modeling 
(Herzberg and James. 1985; Hai et al. 2002; Kimura et al. 2002; Pirani et al. 
2005; Poole et al. 2006).  Although the exact position of troponin and 
tropomyosin on actin are not fully defined, the movement of tropomyosin to three 
relative positions is well accepted.   
The three conditions that define the states are actomyosin in the absence 
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of calcium, presence of calcium and in the presence of rigor myosin.  The 
positions of tropomyosin in these various conditions are easier to visualize than 
troponin due to tropomyosin’s long helical repeating nature.  The troponin 
complex has been more difficult to examine.  Recently several groups have used 
known crystal structures along with atomic modeling to place the troponin on 
reconstructed thin filaments (Pirani et al. 2006; Poole et al. 2006). 
Structural states may be functionally redundant.  There is a tendency to 
ascribe different functions to each of the three structural states.  Several models 
utilize three states in describing activity.  In particular the Geeves model utilizes 
three states along with a steric blocking mechanism (McKillop and Geeves. 
1993).  There may, however, be redundancy amongst the three structural states, 
and our previous functional assays have shown that altering the distribution 
between only two states is sufficient to explain activity.  Figure 12 shows the 
possible relationships between the structural and functional states.   
Studying these mutations provided us with an unexpected means to further 
delineate between two and three states.  Until there is a necessity for adding an 
additional state, a simpler two state model should be utilized.  The transitions due 
a stabilization of an intermediate state may be apparent with the effects of some 
cardiomyopathy causing mutations that alter the distribution of states. 
Importance of third state.  The distinction between a two state or three 
state model has implications for studying cardiac disease and other muscle  
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Figure 12.  Possible relationships between the different known structural 
states of regulated actin and functional states (inactive, intermediate, and 
active).  Structural diagrams shown are schematic representations of data 
presented by several groups showing tropomyosin positions relative to the long 
axis of actin in the absence and presence of calcium and in the presence of 
bound “activating” cross bridges.  In three state models of regulation each 
structure is associated with a unique function.  In two state models two of the 
structures have the same function.   
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diseases in general.  If a third state has a unique function, such as an 
independent ATPase rate, it will be important to define these properties to 
understand muscle regulation.  The overall activity is a function of the rate of 
each individual pathway and the fraction of each pathway present.  The third 
intermediate state may have a significantly different activity, altering the way we 
understand the overall function of cardiac muscle.   
It may also be the case that particular mutations may stabilize this 
intermediate state.  We cannot properly define the underlying cause of disease 
unless we understand the effects of these mutations on muscle regulation.  By 
determining first whether a third intermediate state is present then determining its 
properties, we will be furthering our understanding of the cardiomyopathies. 
Four Mutations That Cause Hypertrophic and Restrictive Cardiomyopathy 
We studied four mutations on troponin I that are known to cause 
cardiomyopathy.  These mutations are present in the inhibitory segment (R145G 
and R145W) and the C-terminal tail of TnI (D190H and R192H) (Human 
sequence).  The R145W and R192H mutations cause restrictive cardiomyopathy 
while the R145G and D190H are responsible for hypertrophic cardiomyopathy 
(Gomes et al. 2005; Kobayashi and Solaro. 2006).  Our original intent in studying 
these mutations was to expand on our screen of cardiomyopathy causing 
mutations in troponin to determine their effect on the equilibrium between 
actomyosin states.  Choosing these four mutations to further our survey provided 
us with a means to compare the effects on two important domains of TnI, the 
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inhibitory segment and a second actin binding domain at the C-terminus, and to 
compare two types of cardiomyopathy.  In fact different mutations on residue 145 
cause both HCM and restrictive cardiomyopathy. 
Previous studies had examined the ATPase rates of D191H, R193H, 
R146G, and R146W (mouse sequence, corresponding human residues: D190H, 
R192H, R145G and R145W) showing a reduction of the inhibitory capability of 
troponin from 70 percent for wild type to around 10 percent for the R145W 
mutation (The rate in the absence of troponin was considered full inhibition) 
(Gomes et al. 2005).  Results for several of the other mutations showed minor 
changes, both increasing and decreasing, depending on the group and mutation 
(Lang et al. 2002; Gomes and Potter. 2004; Gomes et al. 2005; Kobayashi and 
Solaro. 2006).  Our goal was to determine if these effects were due to changes in 
distributions of thin filament states (i.e. stabilization of either the active or inactive 
state) or to other factors. 
Familial Restrictive cardiomyopathy.  Restrictive cardiomyopathy is 
generally secondary to systemic disorders, but is less commonly present as a 
familial disease (Rose. 2006).  These cases tend to carry a poor prognosis as the 
patient ages.  Although several mutations have been defined as being linked to 
RCM, there is still debate about whether this disease is an independent entity or 
part of the clinical spectrum of HCM (Angelini et al. 1997; Kubo et al. 2007).   
Some of the characteristic features of RCM are normal ventricular wall 
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thickness and nondilated ventricles.  There is increased wall rigidity and 
restrictive diastolic filling, leading to severe diastolic dysfunction.  Systolic 
function of the left ventricle is largely unaffected.  The disease can present at any 
age, but is commonly found in older patients.  In any case of RCM, secondary 
causes must be ruled out to make a diagnosis of familial RCM.  Symptomatic 
patients have a poor prognosis.  Treatment is tailored to reduce systemic and 
pulmonary congestion.  Generally this includes diuretics to reduce pressure or 
calcium channel blockers and β-blockers which may increase diastolic filling time.  
A more thorough understanding of the disease will help develop therapy aimed at 
the primary cause.   
Survey of these mutations is informative on several levels.  Our 
examination of these four mutations will provide us with information about several 
aspects of cardiomyopathy and cardiac muscle regulation.  First, it will help us 
differentiate between different models of regulation.  Although the models are 
simply tools for understanding the disease process, and the results are model 
independent, finding a more accurate system will be helpful in defining further 
mutations.  Primarily we expected to show that the Hill model remained the only 
model that could explain the ATPase rates of these mutants.  As shown in the 
next section, we were also able to modify this model to incorporate three states.   
We will also gain knowledge about the effect of different mutations on the 
same R145 residue in the inhibitory region of TnI.  It is speculated that the 
multiple arginine residues present in this disordered segment play a key role in 
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binding to actin (Lang et al. 2002).  We were interested in determining if the two 
mutations on this residue would both have similar effects as they both remove 
this charge, or whether they would have differing effects as one causes HCM and 
the other RCM.  This information will further inform us about the role of familial 
RCM as a disease and if it should be considered an independent disease or part 
of the spectrum of HCM.  Finally, the two mutations on the C-terminus of TnI will 
help to elucidate the role of this disordered region in cardiac muscle regulation. 
Results 
Determining the Binding Constants of Troponin to Actin 
 Mutations of troponin I could weaken the binding of troponin to actin-
tropomyosin and lead to a loss of regulation.  Troponin has an inhibitory effect on 
ATPases in the absence of calcium.  If troponin affinity to actin-tropomyosin is 
reduced by the mutations, the ATPase rates would be higher than those of wild 
type at similar concentrations.  In the case of increased affinity of troponin to 
actin, the ATPase rates would be lower than wild type. 
We examined the ATPase rates in the absence of calcium with increasing 
concentrations of the troponin complex.  Figure 13 shows initial velocities of ATP 
hydrolysis versus the free concentration of troponin.  The free concentration of 
troponin was determined by assuming full saturation with troponin at the most 
inhibited rate, and a linear relationship between the fraction of inhibition and 
fraction of saturation as detailed in the Materials and Methods section.   
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Figure 13.  TnI mutations have little effect on the concentration of free 
troponin required for 50% inhibition of actin-activated S1 ATPase activity.  
Actin-activated ATPases for wild type and mutants at 0.05 M ionic strength are 
shown with increasing concentrations of troponin in the absence of Ca2+. Initial 
velocities (μM ATP/s/μM S1) are shown for wild type (WT), D191H (A), R193H 
(B), R146G (C) and R146W (D).  All rates were corrected for the ATPase rate of 
S1 in the absence of actin (0.06 μM ATP/s/μM S1). Data are presented as mean 
values ± SD. Conditions are: 250C, pH 7, 0.1 μM S1, 10 μM actin, 4.3 μM 
tropomyosin, 1 mM ATP, 10 mM MOPS, 2 mM MgCl2, 33 mM NaCl, 1 mM 
dithiothreitol, 1 mM EGTA. 
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The estimated dissociation constants ± standard error are: 0.82 ± 0.37 μM 
(wild type), 0.96 ± 0.14 μM (D191H), 0.70 ± 0.22 μM (R193H), 0.97 ± 0.21 μM 
(R146G), and 0.62 ± 0.16 μM (R146W).  These approximate values show that 
there were no large changes in the binding of troponin to actin-tropomyosin due 
to the mutations.  Under the conditions of our experiments the ATPase rates 
reached their lowest point at 3.6 μM troponin in all cases.  We maintained a 
similar ratio of actin:tropomyosin:troponin in all other experiments to ensure that 
observed changes were not due to a difference in binding.   
The data of Figure 13 also show that each mutant was less inhibitory than 
wild type at saturating concentrations of troponin (p < 0.05).  Residue 146 
mutations had the greatest decreases in inhibitory function.  At saturation with 
troponin the rate ± standard deviation (μM ATP/s/μM S1) for the wild type was 
0.12 ± .02.  The rates for the mutants were: 0.17 ± 0.04 for D191H, 0.18 ± 0.02 
for R193H, 0.20 ± 0.04 for R146G, and 0.23 ± 0.04 for R146W.  At lower 
concentrations of troponin, there were no significant differences between the 
rates of the wild type and the mutants (p > 0.05).   
ATPase Rates at Low Concentrations of Myosin 
Figure 14 compares the effect of mutant and wild type troponin on ATPase 
rates in the presence and absence of calcium.  These rates were collected during 
the linear phase of phosphate release, providing the initial velocity at saturating 
troponin and tropomyosin concentrations (actin:troponin:tropomyosin 7:2.5:3).   
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Figure 14.  Rates of actin-activated ATPase measured at near saturating 
concentrations of troponin in the presence (A) and absence (B) of calcium.  
The TnI C-terminal mutants show small changes in the presence of calcium and 
an increased rate in the absence of calcium while both mutations at residue 146 
show large reductions in rate in the presence of calcium and increased rates in 
the absence of calcium.  Data are presented as mean values ± SD. All conditions 
and corrections are similar to Figure 13 except that a constant and nearly 
saturating concentration of troponin was used and 0.5 mM CaCl2 was substituted 
for EGTA in (A). 
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The rates ± standard deviation (μM ATP/s/μM S1) in calcium were: 1.91 ± 
0.11 for wild type, 1.72 ± 0.13 for D191H, 2.05 ± 0.06 for R193H, 0.48 ± 0.06 for 
R146G, and 0.61 ± 0.06 for R146W.  The rates in the absence of calcium were: 
0.13 ± 0.02 for wild type, 0.19 ± 0.03 for D191H, 0.18 ± 0.02 for R193H, 0.23 ± 
0.03 for R146G, and 0.26 ± 0.02 for R146W.  The differences between each 
mutant and wild type were statistically significant in the presence and absence of 
calcium (p < 0.05).  The R193H mutation had a small increase in rate in both the 
presence and absence of calcium.  
The D193 mutation activated the thin filament, increasing the ATPase in 
the presence of calcium by 0.14 s-1 and by 0.05 s-1 in the absence of calcium.  
The D191H mutation had a more complex effect, decreasing the ATPase rate in 
the presence of calcium by 0.19 s-1 and increased the rate in the absence of 
calcium by 0.07 s-1.  We observed more dramatic effects with the R146 
mutations, with over threefold  reductions in rate in the presence of calcium and 
twofold increases in the absence of calcium compared to wild type.  It is 
important to note that both mutations on the R146 residue had similar effects, 
with the R146W mutation showing a slightly larger effect on altering regulation, 
despite being associated with different types of cardiomyopathies.   
These effects were unexpected due to the complex effects of the R146W, 
R146G and D191H mutants which increased activity in the absence of calcium, 
but decreased it in the presence of calcium.  Previously studied mutations either 
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enhanced the rate in both the presence and absence of calcium or reduced it in 
both conditions (Gafurov et al. 2004b; Mathur et al. 2008).  The altered rates in 
residue 146 and 191 mutations could not be explained by assuming stabilization 
of either the inactive or active states.  A stabilization of the active state should 
increase the rates in both the presence and absence of calcium.  A stabilization 
of the inactive state should result in a reduction in calcium and a reduction or no 
change in the absence of calcium. 
These results require either that the mutants stabilize opposite states in 
the absence or presence of calcium relative to wild type, or that they stabilize a 
single third regulatory state with an intermediate activity.  This would allow the 
same shift in equilibrium, towards stabilizing the intermediate state, to explain 
data in both the presence and absence of calcium.  We further analyze this 
possibility in the discussion. 
NEM-S1 Activation of Thin Filament Shows Stabilization of Intermediate State 
N-ethylmaleimide-S1 binds tightly to actin in the presence of ATP, and 
shifts the filament to the active state.  By titrating with this activator, it is possible 
to observe the overall ATPase rate as the regulated filament is shifted to the fully 
active state.  The actin activated ATPase activity of NEM-S1 is very low (0.015 
μM ATP/s/μM S1) and observed rates of ATP hydrolysis can be corrected for the 
contribution due to NEM-S1.  With the fully active state stabilized with NEM-S1 it 
was possible to screen for changes in steps occurring during ATP hydrolysis 
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along the active pathway.   
Figure 15 shows the effect of increasing concentrations of NEM-S1 in the 
presence of calcium.  While there were significant differences between wild type 
values and those of some mutants at low NEM-S1 concentrations, they 
converged at high NEM-S1 concentrations.  At the highest NEM-S1 
concentration used (5 μM) there was no significant differences between any of 
the mutants and the wild type (P > 0.05).  The theoretical curves shown in Figure 
15 were drawn assuming the same limiting velocities in all cases (6.04 μM 
ATP/s/μM S1).  This would be expected as they are all fully in the active state at 
this NEM-S1 concentration.  The data are well described by the theoretical 
curves.  These curves also show that the mutants differed in their sensitivity to 
NEM-S1 concentration.  The D191H and R193H mutations did not show a 
significant difference from wild type at any NEM-S1 concentration.     
The effects of NEM-S1 on ATPase activities in the absence of calcium are 
shown in Figure 16.  The residue 146 mutations had approximately two-fold 
higher rates than wild type when both rates were measured in the absence of 
NEM-S1.  However, the ratio between the rates of wild type and the mutants 
began to converge to 1 as the NEM-S1 concentration increased.  The rates for all 
the mutants and wild type were not significantly different at the highest NEM-S1 
concentration used (7 μM) (p > 0.05).  We could not reach the limiting rate in the 
absence of calcium because of the very high NEM-S1 concentrations required  
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Figure 15.  Actin-activated ATPase activity of S1 with increasing 
concentrations of the activator NEM-S1 in the presence of Ca2+.  Wild type 
rates (circles) are the same in all four panels with the regression shown as a 
solid line for wild type and a dashed line for the mutant (squares).  The Michaelis-
Menten equation was globally fit to the data using a maximal rate of 6 s-1 with 
varying KMs for each data set (WT = 5.5 μM, D191H = 6.1 μM, R193H = 6.1 μM, 
R146G = 3.4 μM, and R146W = 2.9 μM).  All rates were corrected for the 
ATPase rate of S1 and NEM-S1 (0.015 μM ATP/s/μM NEM-S1).  Data are 
presented as mean values ± SD.  Conditions are: 25oC, pH 7, 0.1 μM S1, 10 μM 
free actin, 1 mM ATP, 10 mM MOPS, 3 mM MgCl2, 33 mM NaCl, 1 mM 
dithiothreitol, 0.5 mM CaCl2. Actin concentration was increased by an amount 
equal to the NEM-S1added to maintain the same free actin concentration.  
Actin:tropomyosin:troponin was 7:3:2.5. 
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Figure 16.  Actin-activated ATPase activity of S1 with increasing 
concentrations of the activator NEM-S1 in the absence of Ca2+.  Wild type 
rates (circles) are the same in all panels with the regression shown as a solid line 
for wild type and a dashed line for the mutants (squares).  The Michaelis-Menten 
equation was fit to the data using a maximal rate of 6 s-1 with independently 
varying KMs for each data set (WT = 9.8 μM, D191H = 9.6 μM, R193H = 9.3 μM, 
R146G = 7.1 μM, and R146W = 6.7 μM).  All conditions and corrections are 
similar to Figure 15 with the exception that CaCl2 is replaced with 1 mM EGTA. 
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and the associated large errors.   Figure 16 shows theoretical curves for all low 
calcium data sets assuming the same limiting rate as in Ca2+.  All previous 
studies have shown that at high concentrations of tight binding forms of S1, the 
thin filament is in the fully active state.  The rate at this concentration would be 
the same as the rate in the presence of calcium.  The curves represent the data 
well.  As in Ca2+, the R146G and R146W mutants had a greater sensitivity to 
NEM-S1. 
Concentration Curves Require a Similar Actin Concentration To Reach Half-
Maximal Activity 
 A shift in the equilibrium between states will alter the maximal ATPase 
rate at high actin concentration, but will not shift the concentration of actin 
required for half maximal activation.  We measured ATPase rates with increasing 
concentrations of actin and generated a fit using Michaelis Menten parameters.  
Figure 17 shows the results for differing actin concentrations with wild type and 
the R146W mutation.  We chose this mutation as it had the largest impact on 
regulation.  The wild type values were: Vmax = 23 and Km = 117.  The residue 
R146W mutation values were: Vmax = 5.8 and Km = 110.  This provided further 
evidence that this mutation shifts the equilibrium towards the intermediate state. 
Discussion 
We studied these four cardiomyopathy causing mutations to determine if 
altering the distribution between actin states is a common mechanism by which  
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Figure 17.  Actin activated ATPases with a fixed concentration of S1 (0.1μM) 
and varying concentrations of actin in the presence of calcium.  Circles 
represent wild type and squares represent R146W.  The data were fit to a 
Michaelis-Menten equation.  Wild type Vmax = 23 and Km = 118.  R146W Vmax 
= 5.8 and Km = 111. 
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mutations cause disease.  We first determined the saturating concentrations of 
troponin and tropomyosin required to achieve full inhibition.  At near saturating 
concentrations of troponin, all four mutants showed statistically higher ATPase 
rates than wild type in the absence of calcium.  These results also show that 
there are not large differences in apparent affinity between the mutants and wild 
type. The changes seen with the mutations could have been due to alterations of 
the rate of some process along the active pathway (i.e. product release).  By 
using NEM-S1 it was possible to stabilize the fully active state of the actin 
filaments.  No differences were observed in the rates of ATP hydrolysis between 
the wild type and mutants under these conditions.  Thus it is unlikely that rates of 
transitions between two nucleotide bound states are affected by the mutations of 
TnI.   
The remaining possibility is that these mutations of troponin I alter the 
equilibrium among states of regulated actin.  For example, the increased rate in 
both the high and low Ca2+ seen with the R193H mutation can be rationalized by 
stabilization of the most active state of regulated actin.  A similar shift to the 
active state was reported with the Δ14 mutation on TnT (Gafurov et al. 2004b).  
The D191H, R146G and R146W mutants exhibit the property of being more 
active in EGTA and less active than the wild type at saturating calcium.  These 
results require either that the mutants stabilize opposite states in the absence or 
presence of calcium relative to wild type (the two state model), or that they 
stabilize a single third regulatory state with an intermediate activity.   
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The effect of the mutations on the distribution of states in the presence 
and absence of calcium is shown for a two state model (Figure 18A).  Calcium 
binds more tightly to the active state (K4>K1) so that the active state is stabilized 
by calcium.  The D191H, R146G and R146W mutants would need to shift the 
equilibrium constant K3 to the right and K2 to the left compared to wild type to 
explain the ATPase rates (heavy arrows in Figure 18A).  It is difficult to imagine 
structurally how a mutation that stabilizes the active state at low calcium relative 
to the wild type can at the same time produce a relative stabilization of the 
inactive state at saturating calcium.  Detailed structural studies will further clarify 
whether such a mechanism is possible. 
It is more likely that conformational changes due to the mutations will 
cause actin filaments to favor a single structure that corresponds to a unique 
functional state.  That is, the intermediate structural state proposed to exist in 
regulated actin filaments is a unique functional state.  The bold arrows in Figure 
18B indicate possible changes in equilibrium constants of TnI mutants that would 
give the observed ATPase rates while avoiding opposing changes of a single 
step.  This scheme requires that the intermediate has an ability to stimulate 
ATPase activity that is greater than that of the inhibited state but less than that of 
the fully active state.  An examination of the distributions is shown later in this 
discussion.   
It is interesting to note that the two mutations at residue 146 have similar  
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Figure 18.  Possible effects of R146G and R146W mutations on the 
distribution of actin states in the presence (Ca2+) and absence (0) of 
calcium.  In wild type filaments, the equilibrium favors state i0 in the absence of 
calcium and aCa2+ in the presence of calcium.  (A) Two state model with inactive 
(i) and active (a) states.  (B) Three state model with inactive (i), intermediate (x), 
and active (a) states.  The heavy arrows show the changes in equilibrium 
constants required to explain the results of the mutants.  (C) Altered schematic 
showing the modified Hill model with three states.  Ai (inactive), Ax (intermediate), 
Aa (active), MATP (myosin-ATP), MADP (myosin-ADP).  Compare to Figure 4. 
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patterns of ATPase activity.  It may be the case that the significant change is the 
loss of the basic arginine instead of the amino acid that replaces it.  It has been 
shown in skeletal troponin that arginine and lysine residues on the troponin 
mobile domain are important in stabilizing the interaction with actin (Levine et al. 
1988).  Examining other mutations at this site and other cardiac troponin basic 
amino acids may help refine this mechanism.   
In the parallel pathway model, the overall actin-tropomyosin-troponin 
stimulated myosin ATPase rate is given by the sum of the product of the fraction 
of myosin bound to each actin state and the activity of each state.  Because S1-
ATP binds with a similar affinity to myosin in the calcium free, calcium bound and 
NEM-S1 stabilized active states this is equivalent to the sum of the product of the 
activity of each state times the fraction of actin in each state.  In the original 
parallel pathway Hill model we assumed that there were two states as in Figure 
18A.  Calcium was thought to increase the ATPase activity by increasing the 
population of the active state.  That is, in Figure 18A the affinity of calcium for the 
active state is greater than that for the inactive state.  Therefore, calcium 
increases the fraction of actin in the active state.  If another state is included in 
the Hill model as in Figure 18B the observed ATPase rate could be determined 
by the following equation: 
vobs = fi*vi + fx*vx + fa*va 
Where fi, fx and fa are the fractions of total actin in each state and where vi, vx 
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and va are the activities of the respective states.  
In order to place limits on the distributions of states it is necessary to 
define the activities of the individual states.  Because the ATPase rates at 
optimum concentrations of NEM-S1 are calcium-independent it is likely that 
under this condition virtually all of the regulated actin is in the active state.  This 
result also implies that the activity of the fully active state is calcium independent.  
We made the simplifying assumption that the activities of the other states are 
also calcium independent.   
The activity of the inactive state must be between 0 and the lowest rate 
that we have measured (0.13/sec).  We assumed that the inactive state had a 
true rate of 0.1/sec.  Essentially no actin is in the fully active state in EGTA in 
accord with our data with the pyrene tropomyosin probe. 
The key uncertain parameter is the activity of actin filaments in the intermediate 
state, vx.  Figure 19A shows the possible values of the fractional occupancy of 
the intermediate state, fx, as a function of the assumed activity of the 
intermediate state, x, in the absence of calcium for wild type and the two 
mutations at residue 146.  The minimum value of vx that is consistent with the 
data for the R146W mutation is 0.26/sec.  At that limiting value, however, the 
equilibrium would be shifted totally to the intermediate state which does not seem 
to be reasonable.  Therefore, the value of vx is likely to be greater than 0.26/sec.  
The maximum value for vx is approximately 0.9/sec (see below) so the activity of  
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Figure 19.  Possible distributions of states for wild type and R146 mutants.  
A) Occupancy of the intermediate state as a function of assumed ATPase rates 
for the intermediate state (vx).  At any given vx, the fractional population of the 
intermediate state is higher for the mutations than the wild type.  The activities of 
the inactive and active states are assumed to be 0.1/sec and 6/sec, respectively.  
An ATPase rate less than 0.26/sec would require a fraction larger than 1.0 for the 
intermediates state in the case of R146W, limiting vx to this minimum rate.  B) 
and C) show the fraction of states in the intermediate and active states for 
different assumed fractions in the inactive state in the presence of saturating 
calcium.  B) Possible distributions for the minimum possible value of vx, 0.26/sec 
with “X” indicating the intermediate state and “A” representing the active state.  
C) Same as B but with vx = 0.85/sec.  At this point the lowest possible fraction of 
the inactive state for the R146G mutation in saturating calcium is 0.5.   
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vx is most likely 4-15% that of the active state under the conditions used in these 
assays. 
Figure 19B and C show distributions for wild type and R146G at two 
extreme possible values of vx.  The maximum possible value for vx is limited by 
the overall rate for the R146G mutant.  That rate is lower than the wild type value 
in calcium.  At values of vx greater than 0.85/sec the major state occupied is the 
inactive state.  At this point the 3-state model would have the same difficulty as 
the 2-state model (Figure 18) in that the mutation would stabilize opposite states 
in the absence and presence of calcium.  This also means that if the absolute 
value of fx is determined, it places further restrictions on the mutant distribution.  
That is, distributions where fx (mutant) < fx (wild type) were not considered.  The 
present analysis of a small number of mutations has resulted in a fairly low range 
of values for the activity of the intermediate state.  This range will change slightly 
once the value of the activity of actin in the inactive state is refined.  The 
distribution of actin states in calcium is sensitive to the activity of the 
intermediate, vx, state so that we can only give ranges of values at the present 
time.  Nevertheless these constraints are already useful in relating other 
observables such as binding kinetics or probe fluorescence changes to functional 
actin distributions.  It is important to improve the estimate of functional state 
distributions so that these other readily available methods may be used to 
confidently determine the time course of changes in functional state distributions.    
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The intermediate state has a cofactor activity similar to the inactive state 
(less than 15 percent that of the active state).  However, the intermediate state 
has a calcium affinity greater than that of the active state (calcium stabilizes the 
intermediate state).  Our results predict that stabilization of the intermediate state 
should increase the calcium sensitivity while decreasing the maximum function of 
the myofilaments.  This is in fact the case.  Other groups have shown both an 
increase in the calcium sensitivity for ATPase rates and a reduction in the relative 
maximal force for the residue 145 mutations (Gomes et al. 2005; Kobayashi et al. 
2006). 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER IV:  CARDIOMYOPATHY CAUSING MUTATIONS ON 
TROPOMYOSIN ALSO SHIFT THE EQUILIBRIUM BETWEEN ACTOMYOSIN 
STATES 
Introduction 
Both mutations on tropomyosin and troponin have been linked to 
hypertrophic cardiomyopathy.  We studied three mutations on tropomyosin that 
cause HCM:  V95A, E180G and D175N.  V95A in particular has been associated 
with a high mortality rate, although the gross pathological changes to the heart 
are mild (Karibe et al. 2001).  We were interested in determining whether 
mutations on tropomyosin have a similar mechanism of action as 
cardiomyopathy causing mutations on troponin.   
The equilibrium between actomyosin states depends on both troponin and 
tropomyosin.  These two regulatory proteins act as a single cooperative unit 
shifting the distribution of states from the inactive in the absence of calcium to the 
active in the presence of calcium.  It is likely, then, that both of these proteins will 
have similar effects on regulation when altered by disease causing mutations. 
Mutations at Residues 175 and 180 Lie in the Troponin T Binding Region 
The primary site of interaction between troponin and tropomyosin lies 
between residues 160-220, which includes the residues for two of our disease 
causing mutations (Kremneva et al. 2004).  Studies in transgenic mouse lines 
show that D175N mutations have a high mortality rate, while E180G has a lower 
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mortality rate (Muthuchamy et al. 1999).  Both of these mutations lead to partial 
unwinding of the tropomyosin coiled coil (Golitsina et al. 1999).  Studying both of 
these mutations should allow us to further correlate functional and clinical 
outcome to the underlying changes in regulation.  One of the questions we are 
interested in answering is whether these disparate mutations have different 
effects on the distribution between actomyosin states or are similar due their 
structural proximity.   
V95A Mutation Has a Poor Prognosis 
 The survival rate with this mutation at 40 years is approximately 73 
percent.  This is, however, accompanied by mild hypertrophy (maximum of 16 
mm) and no left ventricular outflow obstruction (Karibe et al. 2001).  The 
relationship between this odd combination of high mortality and mild pathology 
with the alterations in actomyosin regulation will further help characterize the 
correlation between regulatory changes and phenotype.   
Deletions of this portion of tropomyosin have been shown to reduce the 
ability of the regulated thin filament to become fully active (Landis et al. 1997).  
This deletion does not alter the ability of tropomyosin to inhibit actomyosin 
activity as saturating tropomyosin concentrations.  Our studies of ATPases at low 
and high myosin concentrations will determine whether the V95A mutation also 
has this effect. 
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Do Troponin and Tropomyosin Have Similar Mechanisms of Action? 
 Our primary goal is to determine if these tropomyosin mutations shift the 
equilibrium between states as the troponin mutations do.  If so, this will further 
prove our hypothesis that cardiomyopathies can be grouped according to their 
effects on the distribution of states, and a therapy targeted at this mechanism will 
be effective against a large class of mutations. 
Results 
D175N and E180G Have an Increased ATPase Rate as Compared to Wild Type 
With Sub-saturating Tropomyosin and Troponin While V95A Has a Similar Rate 
 We began by determining the concentration of tropomyosin required to 
reach a steady minimal rate for each of the mutations and wild type (Figure 20).  
At all concentrations of tropomyosin the rates for D175N and E180G were higher 
than wild type.  The rates at saturating concentrations of tropomyosin were:  wild 
type 0.17 s-1, D175N 0.37 s-1, and E180G 0.39 s-1. 
 The rates for V95A were similar to wild type at all concentrations of 
tropomyosin.  The rates at saturating concentrations of tropomyosin were:  wild 
type 0.17 s-1 and V95A 0.19s-1. 
D175N and E180G Show Increased ATPase Rates While V95A Shows Reduced 
Rates With Varying Concentrations of Troponin 
 After determining the saturating concentration of tropomyosin, we 
examined the rates with varying concentrations of troponin (Figure 21).  We  
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Figure 20.  ATPase rates at low myosin concentrations with varying 
concentrations of tropomyosin and a fixed troponin concentration of 1.5 
μM in the absence of calcium.  E180G and D175N show increased rates 
compared to wild type at all tropomyosin concentrations.  V95A shows a similar 
rate at all concentrations of troponin.  [S1] = 0.1 μM, [Actin] = 10 μM, temperature 
= 25oC, pH = 7. 
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Figure 21.  ATPase rates at low myosin concentrations with varying 
concentrations of troponin in the presence of calcium.  E180G and D175N 
show increased rates at low troponin concentrations.  V95A shows a reduced 
rate at all concentrations of troponin.  [S1] = 0.1 μM, [Actin] = 10 μM, temperature 
= 25oC, pH = 7. 
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found that at saturation tropomyosin concentrations with low troponin 
concentrations both the D175N and E180G mutations showed an increased 
ATPase rate in the presence of calcium.  As the concentration of troponin was 
increased the rates of the mutants became similar to wild type.  The rates at low 
troponin concentrations are:  wild type 1.79 s-1, D175N 2.18 s-1, and E180G 2.47 
s-1.  At high troponin concentrations the rates are:  wild type 1.24 s-1, D175N 1.27 
s-1, E180G 1.29 s-1. 
 V95A, in contrast, has a lower ATPase rate than wild type at low troponin 
concentrations in the presence of calcium.  This difference is maintained at 
saturating concentrations of troponin, though the difference is small.  The rates at 
low troponin concentrations are: wild type 1.79 s-1 and V95A 1.61 s-1.  The rates 
at high troponin concentrations are:  wild type 1.24s-1 and V95A 1.14 s-1. 
Figure 22 shows the results with saturating tropomyosin concentrations 
and varying troponin concentrations in the absence of calcium.  At low 
concentrations of troponin both the E180G and D175N mutations result in a 
higher ATPase rate than wild type.  At saturating troponin concentrations, both 
these mutations have similar rates to wild type.  These results mirror the results 
in the presence of calcium, indicating an activation of the filament, although only 
at low troponin concentrations.  The ATPase rates at low troponin concentrations 
are:  wild type 0.14 s-1, D175N 0.24 s-1, E180G 0.26 s-1.  The rates at high 
troponin concentration are:  wild type 0.10 s-1, D175N 0.10 s-1, E180G 0.08 s-1. 
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Figure 22.  ATPase rates with varying troponin concentrations in the 
absence of calcium at low myosin concentrations.  E180G and D175N show 
a higher ATPase rate as compared to wild type at low troponin concentrations.  
V95A has a lower ATPase rate than wild type.  Conditions are similar to Figure 
21 except for the absence of calcium and the presence of 1 mM EGTA. 
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The V95A mutation shows a reduction in ATPase rate at both high and 
low troponin concentrations.  This is similar to the rates in the presence of 
calcium, indicating an inhibition of activity by V95A as compared to wild type.  
The rates at low troponin concentrations are:  wild type 0.14 s-1 and V95A      
0.12 s-1.  The rates at high troponin concentrations are:  wild type 0.10 s-1 and 
V95A 0.07 s-1.   
ATPase Rates in the Presence of High Concentrations of Myosin 
 Figure 23 shows the ATPase rates for wild type and all three tropomyosin 
mutations with increasing concentrations of NEM-S1 in the presence of calcium.  
The rates for D175N and E180G were similar to  wild type at all concentrations of 
NEM-S1.  The rates at saturating concentrations of NEM-S1 were:  wild type 1.82 
s-1, D175N 1.83 s-1, E180G 1.89 s-1. 
 The rates of V95A were lower than wild type at all concentrations of NEM-
S1.  At higher concentrations, however, the ratio of rates was closer to 1 than at 
lower concentrations, indicating a convergence of rates.  The rates at the highest 
concentration of NEM-S1 were:  wild type 1.82 s-1 and V95A 1.72 s-1.  The ratio 
at 0 μM NEM-S1 for V95A:wild type is 0.92.  The ratio at the highest NEM-S1 
concentration is 0.95. 
 Figure 24 shows the ATPase rates for wild type and the tropomyosin 
mutants with increasing NEM-S1 concentrations in the absence of calcium.  The 
rates of D175N and E180G are similar to wild type at all concentrations of NEM- 
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Figure 23.  ATPase rates in the presence of calcium with increasing amount 
of NEM-S1 and saturating amounts of troponin and tropomyosin.  
Conditions are similar to Figure 21 except for varying NEM-S1 and a 
corresponding increase in actin. 
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Figure 24.  ATPase rates in the absence of calcium with increasing amount 
of NEM-S1 and saturating amounts of troponin and tropomyosin.  
Conditions are similar to Figure 23 except for the absence of calcium and 
addition of 1 mM EGTA. 
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S1.  The rates at saturating concentrations of NEM-S1 are:  wild type 1.21 s-1, 
D175 1.21 s-1, and E180G 1.23 s-1. 
 The rates for V95A are lower than wild type at all concentrations of NEM-
S1.  The rates begin to diverge as the NEM-S1 concentration is increased.  The 
rates at the highest recorded NEM-S1 concentration are:  wild type 1.21 s-1 and 
V95A 0.95 s-1. 
D175N and E180G Alter In Vitro Motility While V95A Does Not 
 Our collaborators in the Chase laboratory measured the in vitro activity of 
the mutations as compared to wild type (Figure 25).  Both D175N and E180G 
show a marked increase in calcium sensitivity.  V95A is similar to wild type. 
All Three Mutants Reduce α-helical Content of Tropomyosin 
 Our collaborators in the Chase laboratory measured the circular dichroism 
of tropomyosin for wild type and the three mutations (Figure 26).  All three 
reduced alpha helical content.  E180G and D175N had similar structures while 
V95A had a lower helical content. 
Discussion 
These three mutations on tropomyosin show a shift in the equilibrium towards the 
intermediate state for E180G and D175N, and a shift to the inactive state for 
V95A.  The mechanism for the shift towards the intermediate state caused by 
E180G and D175N is different from that seen with troponin mutations. 
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Figure 25.  Mutations increase Ca2+-sensitivity of in vitro motility speed.  
(A) a-GS-Tm WT (●); (B) a-GS-Tm V95A (▼); (C) a-GS-Tm D175N (▲); or (D) a-
GS-Tm E180G.  Both D175N and E180G increase calcium sensitivity while V95A 
is similar to WT.  Data courtesy of the Chase Laboratory. 
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Figure 26.  Mutations decrease a-helix content of tropomyosins as 
compared to wild type.  Circular dichroism spectra of WT and mutant 
recombinant tropomyosins.  Each spectrum is the average of 2 – 3 independent 
determinations.  Data for E180G and D175N are similar to each other and 
different from V95A.  Data courtesy of the Chase Laboratory. 
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 The ATPase with sub-saturating troponin and tropomyosin shows an 
alteration in the binding of tropomyosin due to the mutations at D175N and 
E180G.  Even at high tropomyosin concentrations, the inhibition seen with these 
two mutations is reduced compared to wild type.  It requires saturating 
concentrations of troponin, which increase tropomyosin binding, to reach similar 
inhibition for wild type and these two mutations. 
 At saturating concentrations of troponin and tropomyosin, the D175N and 
E180G mutations show similar behavior to wild type.  This is true both in the 
presence and absence of calcium and with high and low concentrations of 
mysosin.  This indicates that the distribution of states is not altered when the 
regulatory proteins are at saturating levels.  Instead these two cardiomyopathy 
mutations reduce the binding of either troponin or tropomyosin to actin.  At sub-
saturating levels of these two regulatory proteins, however, this is essentially the 
same as stabilizing the intermediate state of actomyosin.  The intermediate state 
has similar ATPase rates as actin-tropomyosin in the absence of troponin.  It may 
be possible that the physiological concentrations of troponin are insufficient to 
allow for saturating binding of tropomyosin with the D175N and E180G mutants, 
leading to cardiac activation and cardiomyopathy.  These two mutations may 
either inhibit tropomyosin binding to actin or reduce tropomyosin’s ability to 
stabilize the troponin-actin interaction. Future experiments that directly measure 
binding of tropomyosin to actin in the absence of troponin will differentiate 
between the two possibilities. 
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 The V95A shows a stabilization of the inactive state similar to that seen 
with the troponin cardiomyopathy causing mutations.  The reduction in rates in 
both the presence and absence of calcium in the presence of high and low 
myosin concentrations are similar to the pattern seen with the phosphomimetic 
mutants detailed in Chapter II.  The increase in the ratio of V95A:wild type rates 
at higher NEM-S1 concentrations strongly indicates a shift in equilibrium  
 The data collected by our collaborators corresponds to our own results in 
two important aspects.  The increase in calcium sensitivity for the D175N and 
E180G mutations indicates a stabilization of the active state as seen from our 
data.  There is no change in the sensitivity, however of V95A.  This may be due 
to differences in the ratio of tropomyosin:troponin:actin.  At low concentrations of 
either troponin or tropomyosin, D175N and E180G show a significant increase in 
rate as compared to wild type.  In contrast, the reduction in rate seen with V95A 
is small to nonexistent at sub-saturating levels of regulatory proteins.  So at these 
lower concentrations of troponin and tropomyosin it will be easier to detect an 
increased sensitivity due to D175N and E180G than it will be to detect a 
reduction due to V95A. 
 The other important aspect in which our data corresponds to Dr. Chase’s 
is that both E180G and D175N show similar results for the in vitro motility and the 
circular dichroism, while the V95A is dissimilar to both of them.  This is also seen 
with our results.  There is not enough information about the relationships 
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between structure and function to make specific correlations between the circular 
dichroism results and our ATPases, but the similarities indicate that a correlation 
exists.   
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER V:  GENERAL DISCUSSION 
Shifting Cardiac Thin Filament Regulation is an Important Modulator of 
Disease 
 The primary goal of these projects was to determine the mechanism of 
action by which cardiomyopathy causing mutations result in cardiac remodeling 
and subsequent disease.  I also wished to determine if there was a physiological 
modifier that could reverse this process.   
Our lab had already shown that the Δ14 and R92Q troponin T mutations, 
which are associated with hypertrophic cardiomyopathy, appear to alter the 
equilibrium between actomyosin states by stabilizing the active state (Gafurov et 
al. 2004b).  We have now shown that several other mutations also alter this 
equilibrium (Mathur et al. 2008; Mathur et al. 2009).   
 We chose protein kinase C phosphorylation of troponin I as a 
physiological modification with high potential for reversing the effect of 
cardiomyopathy mutations because of its inhibitory functional effects.  The 
regulation of PKC phosphorylation in the heart as detailed in Chapter II shows 
the complexity of using this modification as a therapeutic target.  However, the 
spatial organization within the heart, along with higher activity for some isoforms 
over others, gives an indication that the desired isoform of PKC can be targeted.  
Before exploring possible methods of selectively activating various isoforms of 
PKC, it was first necessary to show the feasibility of using this molecule to 
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alleviate cardiomyopathies.  It was also important to understand the underlying 
mechanism of action for this modification to further explore its role in the end 
stages of cardiomyopathies leading to heart failure.    
We have demonstrated that PKC phosphorylation of TnI alters the same 
step as the cardiomyopathy causing mutations Δ14 and R92Q on TnT, except 
PKC stabilizes the inactive state.  This indicates that it is an adaptive response in 
the heart, and increasing its activity has the potential for reversing the secondary 
effects of the disease.  Another potential target is protein kinase A, which is also 
an important physiological regulator of heart function.  One of the future goals of 
the laboratory is to examine protein kinase A to determine its effect on 
sarcomeric regulation.   
It was important to demonstrate the generality of shifting the equilibrium 
between actomyosin states as a modulator of cardiac regulation.  Our study of 
four cardiomyopathy mutations showed that all of them shifted the equilibrium 
among states, but not to the same extent or in the same direction.  As outlined in 
Chapter III, the two mutations at residue 145 on TnI showed a significant change 
that appeared to stabilize a functional intermediate state.  The mechanism of 
action is therefore similar in terms of shifting the equilibrium between states, but 
the direction is altered with these mutations as compared to the Δ14 and R92Q 
mutations on TnT, R193H on TnI and also the PKC mutations.  The 
cardiomyopathy causing mutations on tropomyosin also altered the equilibrium 
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between states, although not always in the same fashion as the troponin 
mutations.  The D175N and E180G stabilized the intermediate state at low 
concentrations of troponin or tropomyosin by decreasing tropomyosin binding, 
and V95A stabilized the inactive state.   
We have established that the distribution of states is an important 
common regulatory mechanism for several disease causing mutations, indicating 
that this could be a common mechanism by which these mutations cause 
disease.  Table 1 details the mutants studied in this work, their effects on 
myofilament activity, and which actomyosin state appears to be stabilized by the 
mutant’s impact on the equilibrium amongst states. 
Our Results Show That an Allosteric Regulation of Thin Filaments Can 
Explain the ATPase Rates 
 Developing an appropriate model of regulation is important for determining 
the underlying cause of disease.  The Hill model is based on an allosteric system 
of regulation, while the Geeves model is based on a steric blocking mechanism.  
Steric blocking has been used to simulate binding of myosin to actin, but has not 
been able to explain the effect of calcium on the kcat and Km of actin activated 
ATPase activity.  Our results in this study, along with previous results from our 
lab, show that tight binding forms of myosin can activate the thin filament in both 
the presence and absence of calcium.  This cannot be explained by a sequential 
steric blocking system as described in the Geeves model.  In the case of steric  
115 
 
 
 
 
 
 
 
Table 1.  List of mutations studied in this dissertation, their respective 
effects on myofilament activity and the actomyosin state stabilized as 
compared to wild type. 
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Mutations Activity Stabilized Actomyosin State 
Cardiomyopathy   
TnT Δ14 Increased Active 
TnT R92Q Increased Active 
TnI R145W Mixed Intermediate 
TnI R145G Mixed Intermediate 
TnI D191H Mixed Intermediate 
TnI R193H Increased Active 
Tm V95A Decreased Inactive 
Tm D175N Increased with Sub-Saturating Primarily Change in Binding 
Tm E180G Increased with Sub-Saturating Primarily Change in Binding 
PKC 
Phosphorylation 
  
TnI S44E Decreased Inactive 
TnI S42E/S44E Decreased Inactive 
TnI 
S42E/S44E/T144E 
Decreased Inactive 
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blocking, calcium must first shift the filament from the blocked to the closed state 
in order for myosin to bind and shift the equilibrium to the open state.   
 In the Hill model, both potentiation of ATPase rates and the full activation 
of the thin filament in the absence of calcium are easily explained.  This system 
is a parallel pathway model, where the inactive state can go directly to the active 
state, even if an intermediate state exists.  Although the data are independent of 
the model, a proper understanding of cardiomyopathies requires refinement of 
the distribution and properties of the individual actomyosin states.   
The Hill Model is Easily Modified To a Three State System 
 We began our investigation with the supposition that two functional states 
are sufficient to explain cardiac muscle regulation.  This dissertation has shown 
that certain cardiomyopathy causing mutations, notably R145 and R145G, 
require three states to simulate the ATPase rates.  This is a significant discovery 
in that this functional third state obviously plays an important role in cardiac 
muscle regulation.  It may be possible that other mutations also stabilize this 
state, and a more detailed examination of the properties of the intermediate will 
help both in understanding and treating cardiomyopathy.  So far we have 
narrowed its activity to 4-15 percent that of the fully active state.  It is more 
difficult to determine the distribution of states.  As shown in Chapter III, this 
distribution may vary widely depending on the unique ATPase rate of the 
intermediate state. 
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 One method to further narrow the range of activity and the changes in 
distribution of the intermediate state due to cardiomyopathy causing mutation is 
by studying the rapid kinetics of transition from inactive to active.  By studying 
several mutations that stabilize the inactive, intermediate, and active states we 
may be able to determine the rate constants driving the transition from one state 
to another.  Once we have a better approximation of the distribution, determining 
the unique ATPase rate becomes much simpler. 
Importance to Study of Cardiomyopathies 
 Our understanding of the cardiomyopathies has made significant 
advancements since they were first characterized.  The majority of HCM cases 
can now be linked to a specific sarcomeric mutation, and echocardiography is 
diagnosing patients at younger ages by screening the families of symptomatic 
patients.  Nevertheless, non surgical treatment remains confined to containing 
the symptoms, having a minimal impact on the natural progression of the 
disease.  There are over 60 mutations on troponin and 8 on tropomyosin that 
lead to hypertrophic and restrictive cardiomyopathy, making a search for a 
common treatment seem elusive. 
Muscle contraction, however, is cooperatively regulated at the sarcomeric 
level, indicating that a common mechanism may underlie the secondary 
pathological changes.  As we have shown, the majority of mutations on troponin 
alter a single step, the equilibrium between actomyosin states.  One mutation on 
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tropomyosin had a similar mechanism, while the other two mutations reduced 
binding.  Although it is unlikely that all mutations will share the same mechanism, 
it is probable that a large class can be identified that either stabilize the inactive, 
intermediate, or active states.  
We have also shown that stabilization of any of the three functional states 
can lead to disease.  Therapies that target the primary defect in regulation must, 
therefore, attempt to restore the normal equilibrium amongst the states.  Further 
examination of other physiological signals, such as protein kinase A, and small 
molecules may delineate other potential therapeutic targets.  By narrowing the 
various disease causing mutations into categories based on how they impact the 
equilibrium amongst states, a common therapeutic approach can be envisioned.  
This will have the benefit over current therapies in that it targets the primary 
defect in regulation, raising the possibility of being able to alter or reverse the 
natural progression of the cardiomyopathies in patients. 
 
 
 
 
 
 CHAPTER VI:  MATERIALS AND METHODS 
Protein Preparation  
Actin and myosin were isolated from rabbit back muscle (Kielley and 
Harrington. 1960).  Myosin was digested with chymotrypsin (Worthington 
Biochemical) for 10 minutes at 25oC to produce subfragement-1 (S1), which 
retains the ability to bind to actin and hydrolyze ATP (Weeds and Taylor. 1975).   
Tropomyosin was isolated from bovine cardiac tissue.  Human cardiac 
troponin C in pET3d, mouse cardiac troponin I in pET3d and mouse cardiac 
troponin T in pSBET were expressed as described previously (Kobayashi and 
Solaro. 2006) for the troponin complex used in Chapter II.  Protein concentrations 
were determined by absorbance measurements at 280 nm, corrected for 
scattering at 340 nm, using the following extinction coefficients (ε0.1%) for 280 nm: 
actin (1.15), myosin-S1 (0.75), tropomyosin (0.23), troponin (0.37). 
Expression of troponin C.   
Plasmids were obtained in pET3d vector from Dr. Kobayashi.  XL1-Blue 
cell lines were transformed, plated and incubated overnight in 8L at 37oC.  
Bacteria were sedimented out and resuspended in 100 mL of 5 % sucrose, 1 mM 
EDTA 50 mM Tris/HCl, pH 8.0 and protease inhibitors.  20 mg of lysozyme in 1-2 
mL H2O. were added to the suspension.  The solution was left at room 
temperature for 15 min and then chilled to 4oC and left overnight. 
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A phenyl sepharose column was prepared with 500 mL of 1 M NaCl, 1 mM 
CaCl2 and 50 mM Tris/HCl, pH 8.0.  Protease inhibitors were added to the lysate 
and the mixture was sonicated (20 sec ON/40sec OFF for 5-7 times at 
output level 5 or 6).  The lysate was centrifuged (18,000rpm for 50 min at 4oC).  
CaCl2  was added(final concentration of 5 mM) and MgCl2 (final concentration 1 
mM) to the lysate.  Saturated ammonium sulfate was added to a final 
concentration of 60 percent. 
The solution was centrifuged at 18,000rpm for 20 min at 4oC.  The 
supernatant was collected and pumped onto the phenyl sepharose column.  The 
column was then washed with 500 mL of 1M NaCl, 1 mM CaCl2 and 50 mM 
Tris/HCl, pH 8.0.  This was followed by washing with 500 mL of 1 M NaCl, 0.2 
mM CaCl2 and 50 mM Tris/HCl, pH 8.0. 
The TnC was eluted  with 500 mL 5 mM EDTA and 20 mM Tris/HCl, pH 
8.0.  TnC containing fractions were dialyzed against 1 mM EDTA, 20 mM 
Tris/HCl and 1 mM DTT.  After adding urea to 6 M, the TnC was loaded onto a 
DEAE column. A gradient of 0-0.5 M NaCl in 6 M urea, 1 mM EDTA and 20 mM 
Tris/HCl, pH 8.0 was used to elute the pure TnC. 
Expression of troponin I.  
Bacteria were cultured as detailed for TnC.  The bacterial pellet was 
suspended in 100 mL of STE (5 % sucrose, 1 mM EDTA and 20 mM Tris/HCl, 
pH 8.0).  The suspension was sonicated for 20 sec x 5 or 6 w/output level 5-7 on 
ice.  This suspension was centrifuged at 19 K rpm for 20 min at 4oC and the 
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supernatant was discarded.  The previous two steps of suspension and 
centrifugation were repeated twice.  The precipitate was suspended in 40 mL 6 M 
urea, 1 mM EDTA and 20 mM Tris/HCl, pH 8.0 plus protease inhibitors.  The 
suspension was sonicated for 20 sec x 4 times on ice and centrifuged at 19K rpm 
for 1 hr at 4oC.  The supernatant was collected and DTT was added to bring the 
concentration to 1 mM plus protease inhibitors.   
The suspension was loaded onto an equilibrated DEAE column.  The 
column was washed with 6 M urea, 1 mM EDTA and 20 mM Tris/HCl, pH 8.0 and 
the flow through was collected.  The flow through was loaded onto a SP-HL 
column.  The protein was eluted with a gradient of 0 to 0.4 M NaCl in 6 M urea, 1 
mM EDTA and 20 mM Tris/HCl, pH 8.0.  Saturated ammonium sulfate was 
added to a final concentration of 70 percent.  This solution was centrifuged in a 
Sorvall at 15,000 rpm for 30 minutes.  The precipitate was resuspended in 6 M 
Urea, 1mM EDTA and 20 mM Tris/HCl, pH 8.0. 
Expression of troponin T.  
Bacteria were cultured as described for TnC.  The bacterial pellet was 
washed with 5 % sucrose, 1 mM EDTA, 20 mM Tris/HCl, pH 8.0 and sonicated 
briefly (20 sec x 5) on ice.  The bacteria were then sedimented by centrifugation 
and resuspended in 6 M urea, 1 mM EDTA and 20 mM Tris/HCl, pH 8.0 (20 
mL/2L culture) and protease inhibitors.  The suspension was sonicated for 20 sec 
x 8 times.  The suspension was then centrifuged at 19K rpm for 35-40 min with a 
SS-34 rotor.  The supernatant was collected and saturated ammonium sulfate 
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was added to a final concentration of 30 percent.  This solution was centrifuged 
at 19 K rpm for 30min and the supernatant was collected.  Saturated ammonium 
sulfate was added to 45 percent final concentration and the solution was then 
stirred for 60 minutes at 4oC. This was centrifuged and the supernatant was 
collected.  Saturated ammonium sulfate was added to a final concentration of 60 
percent and the solution was stirred for 60 minutes.  This solution was 
centrifuged and the precipitate collected.  The precipitate was resuspended in 40 
mL of 6 M urea, 1 mM EDTA and 20 mM Tris/HCl, pH 8.0 plus protease 
inhibitors.  The suspension was dialyzed against. 2L 6 M urea, 1 mM EDTA and 
20 mM Tris/HCl, pH 8.0.  The solution was centrifuged at 19 K rpm for 15 min 
and the resulting supernatant was loaded onto an equilibrated DEAE column.  
The protein was eluted with a NaCl gradient of 0-0.4 M.  This troponin containing 
fraction was dialyzed against 6M urea, 0.1 M NaCl, 1 mM EDTA and 50 mM 
Tris/HCl, pH 8.0.  
Reconstitution of troponin complex.   
Each subunit was suspended in a buffer:  6 M urea, 1 M NaCl, 5 mM MgCl2, 
and 20 mM Tris/HCl pH 8.0, 5 mM DTT.  TnC, TnT, and TnI were combined at a 
1:1:1 molar ratio.  The complex was dialyzed against 1 M NaCl, 5 mM MgCl2, 1 
mM DTT and 20 mM Tris/HCl, pH 8.0 overnight.  The dialysis buffer was 
changed in the morning to 0.3 M NaCl, 5 mM MgCl2, 1 mM DTT and 20 mM 
Tris/HCl, pH 8.0.  The dialysis buffer was changed in the afternoon to 0.1 M 
NaCl, 5 mM MgCl2, 1 mM DTT and 20 mM Tris/HCl, pH 8.0 and left stirring 
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overnight.  A Mono-Q column was equilibrated with 0.1 M NaCl, 5 mM MgCl2, 
and 20 mM Tris/HCl, pH 8.0.  The sample was clarified by ultracentrifugation and 
loaded on the Mono-Q.  The column was washed with 0.1 M NaCl, 5 mM MgCl2, 
and 20 mM Tris/HCl, pH 8.0.  The complex was eluted with a gradient from 0.1 – 
0.5 M NaCl, 5 mM MgCl2, and 20 mM Tris/HCl, pH 8.0.   
Expression and reconstitution protocols for troponin courtesy of Dr. 
Kobayashi. 
Determining the ATPase Rates By Release of 32P 
Rates of (γ32P) ATP hydrolysis were determined in the presence and 
absence of calcium at 25oC, pH 7.0 by measuring the release of 32P (Chalovich 
and Eisenberg. 1982).  Experiments were conducted in covered glass tubes, 
minimizing the diameter to prevent excess evaporation.  Four time points were 
taken over a 10-15 minute period over which the production of 32P was linear with 
time so that the measured velocities were initial velocities.  The buffer generally 
contained 1 mM ATP, 3 mM MgCl2, 10 mM MOPS, 34 mM NaCl, 1 mM EGTA or 
0.5 mM CaCl2 and 1 mM dithiothreitol.  ATP was in large excess over the actin 
and myosin concentrations to maintain linearity.  At least 2 mM free magnesium 
is required to measure accurate ATPase rates.   
When measuring rates in the absence of NEM-S1, 10 μM actin and 0.1 
μM S1 was used.  A large excess of actin must be maintained over S1 to prevent 
activation of the thin filament.  ATPase rates measured in the presence of NEM-
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S1 were recorded at several intermediate concentrations of NEM-S1.  The 
concentration of NEM-S1 was increased until the system reached full activation.  
Virtually all of the NEM-S1 added bound to actin under these conditions 
(Schnekenbuhl et al. 1992).  To prevent competitive inhibition of S1 binding, the 
actin concentration was increased by an equal amount to the NEM-S1 added to 
maintain the same level of free actin(Gafurov et al. 2004a).  The ratio of 
actin:tropomyosin:troponin was 7:1.5:1.5.  The rates were adjusted by 
subtracting the low ATPase activity of free S1 and of NEM-S1.  These rates were 
approximately 0.06 s-1 for free S1 and 0.002 s-1 for NEM-S1.  The hydrolytic 
activity of NEM-S1 is not significantly increased upon binding to actin ( < 1.4 fold 
change). 
Equilibrium S1-ADP Binding 
Equilibrium binding was measured by the fractional increase in light 
scattering when titrating an actin solution with myosin S1.  Measurements were 
made using an Aminco Bowman II Luminescence Spectrometer (Thermo 
Electron Corp.) with excitation wavelength at 340 and emission at 360 nm.  
Conditions for the binding experiments were: 25oC, pH 7.0, 0.2 mg/mL bovine 
serum albumin, 14 units/mL hexokinase, 1 mM glucose, 20 μM AP5A, 2 mM 
ADP, 20 mM MOPS, 5 mM MgCl2, 88 mM NaCl, 1 mM dithiothreitol, 1 mM EGTA 
or 0.5 mM CaCl2.  Actin was stored as a 30 μM stock in 4 mM Imidazole (pH 7.0), 
1 mM dithiothreitol, 2 mM MgCl2, and 30 μM phalloidin.   
126 
 
The phalloidin-actin concentration was 0.075 μM and the ratio of 
actin:tropomyosin:troponin was kept at 1:1:1 to ensure full binding of troponin 
and tropomyosin at the low actin concentration used.  A small volume of a 
concentrated S1 stock was added to the reaction mixture in a stirred cuvette; the 
sample was allowed to equilibrate for at least 5 min before measuring the 
fluorescence.  It was important to make each measurement only after the signal 
had stabilized so that the constants determined were equilibrium values.  The 
fluorescence intensity and the concentration of all proteins were corrected for the 
volume change caused by adding S1. The total volume change was maintained 
at less than 10 percent (Gafurov et al. 2004a).  
Values of θ (S1 bound to actin/Total S1) and free S1 concentration were 
calculated using the equations:  θ = (Fmax – Fi)/(Fmax – Fmin) and [S1]Free = [S1]Total 
- θ * [Actin]Total.  Fi is the measured light scattering and Fmax and Fmin are the 
maximal and minimal measured light scattering respectively.  
Calcium Binding 
Ca2+-binding was measured by changes in fluorescence emission intensity 
of IAANS (2-(4'-iodoacetamido-anilino)-naphthalene-6-sulfonic acid) attached to 
Cys-35 of a single Cys mutant cardia troponin C (C84S) as described previously 
(Kobayashi and Solaro. 2006). The probe was excited at 325 nm.  The solution 
conditions were 100 mM NaCl, 5mM MgCl2, 1mM EGTA, 1mM dithiothreitol and 
20 mM MOPS at pH 7.0 and 25oC. The free Ca2+ concentration was calculated 
with the WEBMAXC Standard program (Patton et al. 2004).  Measurements were 
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carried out 3 - 4 times for each complex.  These experiments were conducted by 
our collaborator, Dr. Kobayashi. 
Binding During Steady-State ATP Hydrolysis 
 Binding was measured by co-sedimentation with actin.  S1 (0.1 μM) and 
variable amounts of actin were mixed in a solution containing 3 mM ATP, 10 mM 
MOPS, 5 mM MgCl2, 14 mM NaCl, 1 mM dithiothreitol and 0.5 mM CaCl2 at pH 7.  
Mixtures were centrifuged for 30 min at 25oC at 184,000 x g.  The ammonium-
EDTA ATPase rates of the supernatants were measured to determine the 
fractions of unbound S1 (Chalovich and Eisenberg. 1982).  The fractions of 
bound S1 were determined from conservation of mass considerations.  S1 was 
clarified by centrifugation immediately before use in binding assays. 
Statistics 
Data in figures are shown as means with error bars showing standard 
deviation.  Statistical significance (p < 0.05) was determined using the two-
sample t significance test to compare means. 
Determining Free Troponin Concentration Dependencies 
Plots of ATPase activity as a function of added troponin were constructed.  
The free concentration was determined by assuming that at the plateau of 
activity, 1 troponin and tropomyosin were bound per 7 actin monomers.  The 
amount of troponin bound at each sub maximal concentration was assumed to 
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be proportional to the fraction of the maximum effect on ATPase activity.  With 
this approach the curves were transformed to ATPase rate versus free troponin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 REFERENCES 
 
AHMAD, F., SEIDMAN, J.G. and SEIDMAN, C.E. 2005. The genetic basis for 
cardiac remodeling. Annu. Rev. Genomics Hum. Genet. 6, 185-216. 
ANGELINI, A., CALZOLARI, V., THIENE, G., BOFFA, G.M., VALENTE, M., 
DALIENTO, L., BASSO, C., CALABRESE, F., RAZZOLINI, R., LIVI, U. and 
CHIOIN, R. 1997. Morphologic spectrum of primary restrictive cardiomyopathy. 
Am. J. Cardiol. 80, 1046-1050. 
ARAD, M., SEIDMAN, J.G. and SEIDMAN, C.E. 2002. Phenotypic diversity in 
hypertrophic cardiomyopathy. Hum. Mol. Genet. 11, 2499-2506. 
BELIN, R.J., SUMANDEA, M.P., ALLEN, E.J., SCHOENFELT, K., WANG, H., 
SOLARO, R.J. and DE TOMBE, P.P. 2007. Augmented protein kinase C-alpha-
induced myofilament protein phosphorylation contributes to myofilament 
dysfunction in experimental congestive heart failure. Circ. Res. 101, 195-204. 
BRENNER, B., KRAFT, T., YU, L.C., CHALOVICH, J.M. 1999. Thin Filament 
Activation Probed by Fluorescence of N-((2-(Iodoacetoxy)ethyl)-N-methyl)amino-
7-nitrobenz-2-oxa-1,3-diazole-Labeled Troponin I Incorporated into Skinned 
Fibers of Rabbit Psoas Muscle. Biophys. J. 77, 2677-2691. 
 
BURKART, E.M., SUMANDEA, M.P., KOBAYASHI, T., NILI, M., MARTIN, A.F., 
HOMSHER, E. and SOLARO, R.J. 2003. Phosphorylation or glutamic acid 
substitution at protein kinase C sites on cardiac troponin I differentially depress 
myofilament tension and shortening velocity. J. Biol. Chem. 278, 11265-11272. 
 
BUTTERS, C.A., WILLADSEN, K.A. and TOBACMAN, L.S. 1993. Cooperative 
interactions between adjacent troponin-tropomyosin complexes may be 
transmitted through the actin filament. J. Biol. Chem. 268, 15565-15570. 
CHALOVICH, J.M. 2002. Regulation of striated muscle contraction: a discussion. 
J. Muscle Res. Cell. Motil. 23, 353-361. 
CHALOVICH, J.M. 1992. Actin mediated regulation of muscle contraction. 
Pharmacol. Ther. 55, 95-148. 
CHALOVICH, J.M. 1990. Muscle contraction: muscle fiber studies support 
solution data. Trends Biochem. Sci. 15, 261. 
CHALOVICH, J.M. and EISENBERG, E. 1982. Inhibition of actomyosin ATPase 
activity by troponin-tropomyosin without blocking the binding of myosin to actin. 
J. Biol. Chem. 257, 2432-2437. 
130 
 
CHALOVICH, J.M., CHOCK, P.B. and EISENBERG, E. 1981. Mechanism of 
action of troponin . tropomyosin. Inhibition of actomyosin ATPase activity without 
inhibition of myosin binding to actin. J. Biol. Chem. 256, 575-578. 
DORN, G.W.,2ND and FORCE, T. 2005. Protein kinase cascades in the 
regulation of cardiac hypertrophy. J. Clin. Invest. 115, 527-537. 
DRORY, Y., TURETZ, Y., HISS, Y., LEV, B., FISMAN, E.Z., PINES, A. and 
KRAMER, M.R. 1991. Sudden unexpected death in persons less than 40 years 
of age. Am. J. Cardiol. 68, 1388-1392. 
EBASHI, S. 1972. Separation of troponin into its three components. J. Biochem. 
72, 787-790. 
EATON B.L., KOMINZ D.R., EISENBERG E. 1975. Correlation between the 
inhibition of the acto-heavy meromyosin ATPase and the binding of tropomyosin 
to F-actin: effects of Mg2+, KCl, troponin I, and troponin C. Biochemistry 14, 
2718-2725 
FIFER, M.A. and VLAHAKES, G.J. 2008. Management of symptoms in 
hypertrophic cardiomyopathy. Circulation 117, 429-439. 
FILATOV, V.L., KATRUKHA, A.G., BULARGINA, T.V. and GUSEV, N.B. 1999. 
Troponin: structure, properties, and mechanism of functioning. Biochemistry 
(Mosc) 64, 969-985. 
FINLEY, N.L. and ROSEVEAR, P.R. 2004. Introduction of negative charge 
mimicking protein kinase C phosphorylation of cardiac troponin I. Effects on 
cardiac troponin C. J. Biol. Chem. 279, 54833-54840. 
GAFUROV, B., CHEN, Y.D. and CHALOVICH, J.M. 2004a. Ca2+ and ionic 
strength dependencies of S1-ADP binding to actin-tropomyosin-troponin: 
regulatory implications. Biophys. J. 87, 1825-1835. 
GAFUROV, B., FREDRICKSEN, S., CAI, A., BRENNER, B., CHASE, P.B. and 
CHALOVICH, J.M. 2004b. The Delta 14 mutation of human cardiac troponin T 
enhances ATPase activity and alters the cooperative binding of S1-ADP to 
regulated actin. Biochemistry 43, 15276-15285. 
GOLITSINA, N., AN, Y., GREENFIELD, N.J., THIERFELDER, L., IIZUKA, K., 
SEIDMAN, J.G., SEIDMAN, C.E., LEHRER, S.S. and HITCHCOCK-
DEGREGORI, S.E. 1999. Effects of two familial hypertrophic cardiomyopathy-
causing mutations on alpha-tropomyosin structure and function. Biochemistry 38, 
3850. 
GOMES, A.V. and POTTER, J.D. 2004. Molecular and cellular aspects of 
troponin cardiomyopathies. Ann. N. Y. Acad. Sci. 1015, 214-224. 
131 
 
GOMES, A.V., LIANG, J. and POTTER, J.D. 2005. Mutations in human cardiac 
troponin I that are associated with restrictive cardiomyopathy affect basal 
ATPase activity and the calcium sensitivity of force development. J. Biol. Chem. 
280, 30909-30915. 
GORDON, A.M., HOMSHER, E. and REGNIER, M. 2000. Regulation of 
contraction in striated muscle. Physiol. Rev. 80, 853-924. 
GREASER, M.L. and GERGELY, J. 1971. Reconstitution of troponin activity from 
three protein components. J. Biol. Chem. 246, 4226-4233. 
HABER, E., ed. 1995. Molecular Cardiovascular Medicine, Scientific American, 
New York. 
HAI, H., SANO, K., MAEDA, K., MAEDA, Y. and MIKI, M. 2002. Ca2+- and S1-
induced conformational changes of reconstituted skeletal muscle thin filaments 
observed by fluorescence energy transfer spectroscopy: structural evidence for 
three States of thin filament. J. Biochem. (Tokyo) 131, 407-418. 
HERZBERG, O. and JAMES, M.N. 1985. Structure of the calcium regulatory 
muscle protein troponin-C at 2.8 A resolution. Nature 313, 653-659. 
HILL, T.L., EISENBERG, E. and CHALOVICH, J.M. 1981. Theoretical models for 
cooperative steady-state ATPase activity of myosin subfragment-1 on regulated 
actin. Biophys. J. 35, 99-112. 
HILL, T.L., EISENBERG, E. and GREENE, L. 1980. Theoretical model for the 
cooperative equilibrium binding of myosin subfragment 1 to the actin-troponin-
tropomyosin complex. Proc. Natl. Acad. Sci. U. S. A. 77, 3186-3190. 
JIDEAMA, N.M., NOLAND, T.A.,JR, RAYNOR, R.L., BLOBE, G.C., FABBRO, D., 
KAZANIETZ, M.G., BLUMBERG, P.M., HANNUN, Y.A. and KUO, J.F. 1996. 
Phosphorylation specificities of protein kinase C isozymes for bovine cardiac 
troponin I and troponin T and sites within these proteins and regulation of 
myofilament properties. J. Biol. Chem. 271, 23277-23283. 
KARIBE, A., TOBACMAN, L.S., STRAND, J., BUTTERS, C., BACK, N., 
BACHINSKI, L.L., ARAI, A.E., ORTIZ, A., ROBERTS, R., HOMSHER, E. and 
FANANAPAZIR, L. 2001. Hypertrophic cardiomyopathy caused by a novel alpha-
tropomyosin mutation (V95A) is associated with mild cardiac phenotype, 
abnormal calcium binding to troponin, abnormal myosin cycling, and poor 
prognosis. Circulation 103, 65-71. 
KIELLEY, W.W. and HARRINGTON, W.F. 1960. A model for the myosin 
molecule. Biochim. Biophys. Acta 41, 401-421. 
132 
 
KIMMELSTIEL, C.D. and MARON, B.J. 2004. Role of percutaneous septal 
ablation in hypertrophic obstructive cardiomyopathy. Circulation 109, 452-456. 
KIMURA, C., MAEDA, K., MAEDA, Y. and MIKI, M. 2002. Ca(2+)- and S1-
induced movement of troponin T on reconstituted skeletal muscle thin filaments 
observed by fluorescence energy transfer spectroscopy. J. Biochem. (Tokyo) 
132, 93-102. 
KOBAYASHI, T. and SOLARO, R.J. 2006. Increased Ca2+ affinity of cardiac thin 
filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J. 
Biol. Chem. 281, 13471-13477. 
KREMNEVA, E., BOUSSOUF, S., NIKOLAEVA, O., MAYTUM, R., GEEVES, 
M.A. and LEVITSKY, D.I. 2004. Effects of two familial hypertrophic 
cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on 
the thermal unfolding of actin-bound tropomyosin. Biophys. J. 87, 3922-3933. 
KUBO, T., GIMENO, J.R., BAHL, A., STEFFENSEN, U., STEFFENSEN, M., 
OSMAN, E., THAMAN, R., MOGENSEN, J., ELLIOTT, P.M., DOI, Y. and 
MCKENNA, W.J. 2007. Prevalence, clinical significance, and genetic basis of 
hypertrophic cardiomyopathy with restrictive phenotype. J. Am. Coll. Cardiol. 49, 
2419-2426. 
LAMORTE, V.J., THORBURN, J., ABSHER, D., SPIEGEL, A., BROWN, J.H., 
CHIEN, K.R., FERAMISCO, J.R. and KNOWLTON, K.U. 1994. Gq- and ras-
dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes 
following alpha 1-adrenergic stimulation. J. Biol. Chem. 269, 13490-13496. 
LANDIS, C.A., BOBKOVA, A., HOMSHER, E. and TOBACMAN, L.S. 1997. The 
active state of the thin filament is destabilized by an internal deletion in 
tropomyosin. J. Biol. Chem. 272, 14051-14056. 
LANG, R., GOMES, A.V., ZHAO, J., HOUSMANS, P.R., MILLER, T. and 
POTTER, J.D. 2002. Functional analysis of a troponin I (R145G) mutation 
associated with familial hypertrophic cardiomyopathy. J. Biol. Chem. 277, 11670-
11678. 
LEHMAN, W., HATCH, V., KORMAN, V., ROSOL, M., THOMAS, L., MAYTUM, 
R., GEEVES, M.A., VAN EYK, J.E., TOBACMAN, L.S. and CRAIG, R. 2000. 
Tropomyosin and actin isoforms modulate the localization of tropomyosin strands 
on actin filaments. J. Mol. Biol. 302, 593-606. 
LEVINE, B.A., MOIR, A.J. and PERRY, S.V. 1988. The interaction of troponin-I 
with the N-terminal region of actin. Eur. J. Biochem. 172, 389-397. 
LIM, D.S., LUTUCUTA, S., BACHIREDDY, P., YOUKER, K., EVANS, A., 
ENTMAN, M., ROBERTS, R. and MARIAN, A.J. 2001. Angiotensin II blockade 
133 
 
reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic 
cardiomyopathy. Circulation 103, 789-791. 
MARIAN, A.J. and ROBERTS, R. 2001. The molecular genetic basis for 
hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33, 655-670. 
MARON, B.J. 2002. Hypertrophic cardiomyopathy: a systematic review. JAMA 
287, 1308-1320. 
MARON, B.J., SPIRITO, P., WESLEY, Y. and ARCE, J. 1986. Development and 
progression of left ventricular hypertrophy in children with hypertrophic 
cardiomyopathy. N. Engl. J. Med. 315, 610-614. 
MARON, B.J., SPIRITO, P., GREEN, K.J., WESLEY, Y.E., BONOW, R.O. and 
ARCE, J. 1987. Noninvasive assessment of left ventricular diastolic function by 
pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. 
J. Am. Coll. Cardiol. 10, 733-742. 
MARON, B.J., GOTTDIENER, J.S., ARCE, J., ROSING, D.R., WESLEY, Y.E. 
and EPSTEIN, S.E. 1985. Dynamic subaortic obstruction in hypertrophic 
cardiomyopathy: analysis by pulsed Doppler echocardiography. J. Am. Coll. 
Cardiol. 6, 1-18. 
MARON, B.J., MCKENNA, W.J., DANIELSON, G.K., KAPPENBERGER, L.J., 
KUHN, H.J., SEIDMAN, C.E., SHAH, P.M., SPENCER, W.H.,3RD, SPIRITO, P., 
TEN CATE, F.J., WIGLE, E.D., TASK FORCE ON CLINICAL EXPERT 
CONSENSUS DOCUMENTS. AMERICAN COLLEGE OF CARDIOLOGY and 
COMMITTEE FOR PRACTICE GUIDELINES. EUROPEAN SOCIETY OF 
CARDIOLOGY. 2003a. American College of Cardiology/European Society of 
Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. 
A report of the American College of Cardiology Foundation Task Force on 
Clinical Expert Consensus Documents and the European Society of Cardiology 
Committee for Practice Guidelines. J. Am. Coll. Cardiol. 42, 1687-1713. 
MARON, M.S., OLIVOTTO, I., BETOCCHI, S., CASEY, S.A., LESSER, J.R., 
LOSI, M.A., CECCHI, F. and MARON, B.J. 2003b. Effect of left ventricular 
outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. 
Engl. J. Med. 348, 295-303. 
MATHUR, M.C., KOBAYASHI, T. and CHALOVICH, J.M. 2009. Some 
cardiomyopathy-causing troponin I mutations stabilize a functional intermediate 
actin state. Biophys. J. 96, 2237-2244. 
MATHUR, M.C., KOBAYASHI, T. and CHALOVICH, J.M. 2008. Negative 
charges at protein kinase C sites of troponin I stabilize the inactive state of actin. 
Biophys. J. 94, 542-549. 
134 
 
MCKILLOP, D.F. and GEEVES, M.A. 1993. Regulation of the interaction 
between actin and myosin subfragment 1: evidence for three states of the thin 
filament. Biophys. J. 65, 693-701. 
MONTGOMERY, D.E., WOLSKA, B.M., PYLE, W.G., ROMAN, B.B., DOWELL, 
J.C., BUTTRICK, P.M., KORETSKY, A.P., DEL NIDO, P. and SOLARO, R.J. 
2002. alpha-Adrenergic response and myofilament activity in mouse hearts 
lacking PKC phosphorylation sites on cardiac TnI. Am. J. Physiol. Heart Circ. 
Physiol. 282, H2397-405. 
MORROW, A.G., REITZ, B.A., EPSTEIN, S.E., HENRY, W.L., CONKLE, D.M., 
ITSCOITZ, S.B. and REDWOOD, D.R. 1975. Operative treatment in hypertrophic 
subaortic stenosis. Techniques, and the results of pre and postoperative 
assessments in 83 patients. Circulation 52, 88-102. 
MUTHUCHAMY, M., PIEPLES, K., RETHINASAMY, P., HOIT, B., GRUPP, I.L., 
BOIVIN, G.P., WOLSKA, B., EVANS, C., SOLARO, R.J. and WIECZOREK, D.F. 
1999. Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-
tropomyosin manifests cardiac dysfunction. Circ. Res. 85, 47-56. 
NIIMURA, H., BACHINSKI, L.L., SANGWATANAROJ, S., WATKINS, H., 
CHUDLEY, A.E., MCKENNA, W., KRISTINSSON, A., ROBERTS, R., SOLE, M., 
MARON, B.J., SEIDMAN, J.G. and SEIDMAN, C.E. 1998. Mutations in the gene 
for cardiac myosin-binding protein C and late-onset familial hypertrophic 
cardiomyopathy. N. Engl. J. Med. 338, 1248-1257. 
NODE, K., KITAKAZE, M., SATO, H., MINAMINO, T., KOMAMURA, K., 
SHINOZAKI, Y., MORI, H. and HORI, M. 1997. Role of intracellular Ca2+ in 
activation of protein kinase C during ischemic preconditioning. Circulation 96, 
1257-1265. 
PATTON, C., THOMPSON, S. and EPEL, D. 2004. Some precautions in using 
chelators to buffer metals in biological solutions. Cell Calcium 35, 427-431. 
PIRANI, A., XU, C., HATCH, V., CRAIG, R., TOBACMAN, L.S. and LEHMAN, W. 
2005. Single particle analysis of relaxed and activated muscle thin filaments. J. 
Mol. Biol. 346, 761-772. 
PIRANI, A., VINOGRADOVA, M.V., CURMI, P.M., KING, W.A., FLETTERICK, 
R.J., CRAIG, R., TOBACMAN, L.S., XU, C., HATCH, V. and LEHMAN, W. 2006. 
An atomic model of the thin filament in the relaxed and Ca2+-activated states. J. 
Mol. Biol. 357, 707-717. 
POOLE, K.J., LORENZ, M., EVANS, G., ROSENBAUM, G., PIRANI, A., CRAIG, 
R., TOBACMAN, L.S., LEHMAN, W. and HOLMES, K.C. 2006. A comparison of 
135 
 
muscle thin filament models obtained from electron microscopy reconstructions 
and low-angle X-ray fibre diagrams from non-overlap muscle. J. Struct. Biol. . 
PYLE, W.G., SUMANDEA, M.P., SOLARO, R.J. and DE TOMBE, P.P. 2002. 
Troponin I serines 43/45 and regulation of cardiac myofilament function. Am. J. 
Physiol. Heart Circ. Physiol. 283, H1215-24. 
ROBINSON, K., FRENNEAUX, M.P., STOCKINS, B., KARATASAKIS, G., 
POLONIECKI, J.D. and MCKENNA, W.J. 1990. Atrial fibrillation in hypertrophic 
cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. 15, 1279-1285. 
ROSE, B.D., ed. 2006. UpToDate, UpToDate, Waltham, MA. 
RUSE, C.I., WILLARD, B., JIN, J.P., HAAS, T., KINTER, M. and BOND, M. 2002. 
Quantitative dynamics of site-specific protein phosphorylation determined using 
liquid chromatography electrospray ionization mass spectrometry. Anal. Chem. 
74, 1658-1664. 
SCHNEKENBUHL, S., KRAFT, T., YU, L.C., BRENNER, B., CHALOVICH, J.M. 
1992. Effect of NEM-S-1 on cross-bridge action in skinned rabbit psoas muscle 
fibers.  Biochemical, mechanical, and X-ray diffraction studies. Biophys. J. 61, 
A292. 
SEIDMAN, J.G. and SEIDMAN, C. 2001. The genetic basis for cardiomyopathy: 
from mutation identification to mechanistic paradigms. Cell 104, 557-567. 
SHE, M., TRIMBLE, D., YU, L.C., CHALOVICH, J.M. 2000. Factors contributing 
to troponin exchange in myofibrils and in solution. J. Muscle Res. Cell Motility 21, 
737-745 
SLUPSKY, C.M. and SYKES, B.D. 1995. NMR solution structure of calcium-
saturated skeletal muscle troponin C. Biochemistry 34, 15953-15964. 
SMITH, D.A. and GEEVES, M.A. 2003. Cooperative regulation of myosin-actin 
interactions by a continuous flexible chain II: actin-tropomyosin-troponin and 
regulation by calcium. Biophys. J. 84, 3168-3180. 
TAKEDA S, YAMASHITA A, MAEDA K, MAÉDA Y. 2003. Structure of the core 
domain of human cardiac troponin in the Ca(2+)-saturated form. Nature 424, 35-
41. 
TOBACMAN, L.S. and BUTTERS, C.A. 2000. A new model of cooperative 
myosin-thin filament binding. J. Biol. Chem. 275, 27587-27593. 
VINOGRADOVA, M.V., STONE, D.B., MALANINA, G.G., KARATZAFERI, C., 
COOKE, R., MENDELSON, R.A. and FLETTERICK, R.J. 2005. Ca(2+)-regulated 
structural changes in troponin. Proc. Natl. Acad. Sci. U. S. A. 102, 5038-5043. 
136 
 
WANG, H., GRANT, J.E., DOEDE, C.M., SADAYAPPAN, S., ROBBINS, J. and 
WALKER, J.W. 2006. PKC-betaII sensitizes cardiac myofilaments to Ca2+ by 
phosphorylating troponin I on threonine-144. J. Mol. Cell. Cardiol. 41, 823-833. 
WATKINS, H., MCKENNA, W.J., THIERFELDER, L., SUK, H.J., ANAN, R., 
O'DONOGHUE, A., SPIRITO, P., MATSUMORI, A., MORAVEC, C.S. and 
SEIDMAN, J.G. 1995. Mutations in the genes for cardiac troponin T and alpha-
tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332, 1058-1064. 
WEEDS, A.G. and TAYLOR, R.S. 1975. Separation of subfragment-1 
isoenzymes from rabbit skeletal muscle myosin. Nature 257, 54-56. 
WESTFALL, M.V., LEE, A.M. and ROBINSON, D.A. 2005. Differential 
contribution of troponin I phosphorylation sites to the endothelin-modulated 
contractile response. J. Biol. Chem. 280, 41324-41331.
 APPENDIX 1:  NATIVE THIN FILAMENTS 
 In order to ascertain the true Vmax and KM values for thin filaments, it is 
necessary to work at saturating concentrations of actin.  This is impractical due to 
the high viscosity of solutions with very high actin concentrations and also the 
large expenditure of regulatory proteins to maintain full regulation.  We have tried 
various methods in the lab, including cross-linking S1 to actin, in order to reach 
the true Vmax.  One of the methods we examined was to isolate the thin filament 
from porcine ventricles directly, instead of reconstituting them in vitro.   
 A protocol communicated to us by Dr. Howard White outlines a method to 
extract actin, troponin, and tropomyosin together, so that they have not been 
separated during the extraction process.  One advantage of using these 
filaments is that both the regulatory proteins, troponin and tropomyosin, and the 
actin are all cardiac in origin and from the same species.  The native thin 
filaments also contain additional actin binding proteins, such as nebulin.  Further, 
the original structural organization of the thin filament has been maintained. 
 The other advantage is that these native thin filaments are more likely to 
be capable of reaching full activation at lower concentrations of actin.  We 
measured the ATPase rates of these filaments to determine their ionic strength 
dependence and activation with NEM-S1. 
 Figure 27 shows ATPase rates for the native thin filaments at several actin 
concentrations and ionic strengths.  As the ionic strength is decreased, the  
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Figure 27.  ATPase rates in the presence of calcium at different ionic 
strengths using the thin filament preparation.  The rates were collected at 25 
mM (circles), 50 mM (squares), and 75 mM (triangles) ionic strengths 
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binding of S1 to actin is increased.  This results in a higher rate at lower 
concentrations.  The disadvantage of using a lower ionic strength concentration 
is that we collect fluorometric data at high ionic strengths.  Our goal is to be able 
to compare ATPase rates with binding data gathered from the fluorometer, using 
these two data sets to narrow distributions of actomyosin states.   
 Figure 27 shows that it is possible to reach near the plateau of activation 
at 50 mM ionic strength, though we tend to collect fluorometry data at 120-180 
mM ionic strength.  It is feasible that we could reach near saturating 
concentrations of actin in future experiments. 
 Figure 28 shows the activation of native thin filaments with NEM-S1 at 75 
mM ionic strength.  This was the highest ionic strength where we felt that it would 
be possible to reach near fully saturating actin concentrations.  We then titrated 
with NEM-S1 till we reached full activation for several actin concentrations.  The 
data shows that at this ionic strength, native thin filaments without NEM-S1 
activation have a approximate Vmax of 23 s-1 and Km of 106 μM.  With NEM-S1 
activation the approximate Vmax is 25 s-1 and Km is 66 μM.  The roughly twofold 
activation by NEM-S1 is somewhat less than the three to fourfold increase that 
we see at 50 mM ionic strength with reconstituted skeletal actin filaments. 
 The thin filament preparation is an excellent tool for understanding the 
activation of actin in an intact muscle.  Mutant troponin can be readily exchanged  
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Figure 28.  ATPase rates for thin filament preparation in the presence of 
calcium with and without NEM-S1.  Rates at 75 mM ionic strength without 
NEM-S1 (circles) and with saturating NEM-S1 (squares) are fitted to determine 
maximum rate. 
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into the native thin filaments (Brenner et al. 1999; She et al. 2000), allowing us to 
study cardiomyopathies and physiological modifications in a more native system.   
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